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microRNAs are a class of non-coding RNAs of  21 to 23 nucleotides in length. They 
are endogenously expressed in the majority of eukaryotes. MicroRNAs form protein-
RNA complexes with the RNA-induced silencing complex (RISC) and bind to either 
3’UTR or coding regions of messenger RNAs, causing destabilization of mRNA 
and/or inhibition of protein translation. Animal microRNAs recognize their mRNA 
target via imperfect base pairing. The 5’ position from 2-8nt, the so called “seed 
region”, is critical for microRNAs to repress their targets.  Each miRNA is predicted to 
regulate up to hundreds of genes and more than 65% of the animal genome could be 
potentially targeted by miRNAs. miRNAs play important roles in diverse biological 
processes, including growth, differentiation, neurogenesis, apoptosis and metabolism. 
Misregulation of miRNAs is correlated with various types of human pathologies 
including cancer and directly contribute to disease initiation and progression 
(representative reviews in (Iorio and Croce, 2012; Mendell and Olson, 2012; Rottiers 
and Naar, 2012)).  
 
My PhD project is focused on identification and functional characterizations of 
miRNA-target interactions involved in growth control and cancer transformation. I 
used biochemical  immunoprecipitation against Drosophila Ago1 (Ago1-IP) to isolate 
and purify Ago1/miRNA/mRNA complex and utilized microarray profiling to identify 
mRNAs enriched in Ago1-IP in Drosophila S2 cells. Hundreds of potential miRNA 
targets associated with Ago1 in Drosophila S2 cells were identified by Ago1-IP. 
Computational analysis using the IP-enriched target sets and Ago1 RNAi-upregulated 
target sets suggested the existence of two distinct sets of microRNA targets that exhibit 
substantial differences in molecular and structural properties. My study further 
	   VII	  
revealed a genome-wide correlation between binding site accessibility and the 3’UTR 
length of mRNA targets, suggesting an unprecedented complexity of miRNA-target 
interactions.  
 
One target that I identified from the Ago1-IP is Socs36E, which contains a binding site 
for the growth regulatory microRNA, bantam. Genetic and functional analysis 
suggested Socs36E is a negative growth regulator and contributes to bantam’s loss-of-
function phenotype in the Drosophila wing. Mechanistically, Socs36E negatively 
regulates EGFR activity while EGFR signaling also controls Socs36E expression, 
forming a negative feedback regulatory loop. Socs36E acts as a “brake” to repress 
excessive EGFR signaling and when the “brake” is removed, EGFR overexpression 
leads to uncontrolled tumorous overgrowth and neoplastic transformation. Using an in 
vitro cancer transformation model of primary human fibroblast cells, I further 
demonstrated one of the human orthologs of Socs36E, SOCS5, is a potential 
cooperating tumor suppressor of RasV12/EGF-driven cancer transformation. SOCS5 is 
downregulated in breast cancer samples and associated with ErBB/ER/PR status. 
Lower SOCS5 expression correlates with poorer metastatic-free survival in breast 
cancer patients, suggesting SOCS5 can be a potential biomarker with prognostic value. 
Taken together, through characterization of miRNA-target interactions involved in 
developmental growth control, my collaborators and I have identified the SOCS 
protein family, as oncogenic cooperation factors of EGFR/Ras/MAPK- mediated 
cancer transformation in both Drosophila and human.         
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Chapter 1 Introduction 
 
1.1 The discovery of animal microRNAs 
 
microRNAs are emerging as an important class of post-transcriptional regulators 
involved in diverse biological processes. These 21-23 nucleotides long, endogenously 
expressed small RNAs, recruit RNA-induced silencing complex (RISC) and bind to 
3’UTR as well as coding regions of messenger RNAs, which results in destabilization 
of mRNA and/or inhibition of protein translation.  
The first two animal microRNAs were discovered as heterochronic genes in C. 
elegans. The heterochronic genes regulate timing of developmental transitions in the 
nematode. One such heterochronic gene identified was lin-4. The C elegans lin-4 loss-
of-function mutant stayed in the first larval stage L1 without developing further (Lee et 
al., 1993; Wightman et al., 1993). Furthermore, it was found the 3’untranslated region 
of another heterochronic gene, lin-14, played a critical role to diminish lin-14 protein 
level during developmental transition from L1 to L2 (Wightman et al., 1991). 
Strikingly, lin-4 was found to be a small RNA of about 20-60 bp, that can repress lin-
14 post-transcriptionally via imperfect complementarity to the 3’UTR sequences of 
lin-14. The repression of lin-14 by lin-4 does not involve any nearby known protein 
coding sequences and this mode of regulation is functionally critical for the larvae to 
undergo L1 to L2 transition (Lee et al., 1993; Wightman et al., 1993). Since then, more 
and more such tiny regulatory RNAs, which represses their target mRNAs by direct 
binding, are continuously being discovered as facilitated by the technological 
advancement of next-generation sequencing (NGS). Thanks to NGS, many thousands 
of miRNAs have been discovered in various species and the number is still growing. 
Each miRNA is predicted to regulate up to hundreds of genes and majority of the 
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animal genome could be potentially targeted by miRNAs. Hence, miRNAs represent a 
new class of regulators with intriguing biological functions.   
 
1.1.1 microRNA transcription 
 
Like protein-coding genes, miRNAs are transcribed by RNA polymerase II (Pol II), 
resulting in a long primary transcript with 5’ capped and 3’ polyadenylated (Lee et al., 
2004a). Most miRNAs are intergenic, but a significant fraction of them are located 
within the introns of protein-coding genes. If a miRNA is intronic, it is presumably 
transcribed together with the host gene and can be under the same promoter regulation 
as the host. A few miRNAs occur as clusters in the genome and the whole cluster is 
usually transcribed as a single primary transcripts.  
 
1.1.2 miRNA maturation 
 
The primary miRNA transcript is firstly processed by the “microprocessor” complex, 
composed of RNase III enzyme Drosha and a dsRNA binding domain protein named 
Pasha (partner of Drosha). The Drosha/Pasha complex cleaves the pri-miRNA 
transcript into a ~60-70 nt stem loop precursor miRNA (pre-miRNA, (Allen et al., 
2004; Meister et al., 2004), leaving molecular signatures with a 5’ phosphate and an 
~2nt 3’ overhang. The 3’ overhang of the pre-miRNA is recognized by Exportin-5, a 
Ran-GTP dependent nuclear export factor, and exported to cytoplasm (Bohnsack et al., 
2004; Lund et al., 2004; Yi et al., 2003).  
 
After cytoplasmic export, the pre-miRNA is further processed in the cytoplasm by 
another RNaseIII enzyme called Dicer. Dicer recognizes the 3’ 2nt overhang of the 
pre-miRNAs through its PAZ domain, cleaves the pre-miRNA to produce a mature 
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~22mer miRNA/miRNA* duplex. The miRNA*  (passenger strand) is usually 
degraded rapidly and only the miRNA (leading strand) is predominantly expressed 
(Aravin et al., 2003; Lagos-Quintana et al., 2002; Lau et al., 2001). Drosophila has 
two Dicers, Dicer-1 for miRNA processing and Dicer-2 for endogenous siRNA 
processing respectively. Dicer-1 binds to Loquacious (TRBP in humans), a dsRNA 
binding protein, for efficient production of mature miRNAs from pre-miRNAs (Saito 
et al., 2005; (Haase et al., 2005) and Dicer-2 forms a complex with R2D2, another 
dsRNA binding protein responsible for production of siRNAs (Lee et al., 2004b; Liu et 
al., 2003; Pham et al., 2004).   
 
1.1.3 RISC effector loading 
 
Once the miRNA duplex is formed, the miRNA strand will be preferentially loaded 
into the multi-protein effector complexes called RISC (RNA-induced silencing 
complex). The fact that purified Ago-miRNA complex mainly contain single-stranded 
miRNA suggested a mechanism to unwind the duplex before loading into Ago 
complex is required (Martinez et al., 2002). The loading preference on one strand but 
not the other seems to be dependent on the themodynamic stability of the two ends of 
the duplex: the strand that enters the RISC is the one paired less strongly in the 5’end 
(Khvorova et al., 2003; Schwarz et al., 2003). Fig 1.1 presents a schematic of the 
canonical miRNA biogenesis pathways.  
 
1.1.4 Argonaute proteins as RISC effectors 
 
The core components of RISC consist of members of the argonaute protein family 
(Ago) and GW182 protein family (Hutvagner and Zamore, 2002; Martinez et al., 
2002). As shown in Fig 1.2, Ago are large proteins about 100kDa comprising a single 
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variable N-terminal domain and three conserved C-terminal domains, including the 
PAZ, MID and PIWI domains (Vaucheret, 2008). The N-terminal domain is thought to 
facilitate the separation of the short RNA/target transcript duplex post cleavage. The 
conserved PAZ and MID domains of the C-terminus recognize and anchor the 3' and 5' 
ends of the bound siRNA or miRNA to its target mRNA respectively (Wang et al., 
2008b; Wang et al., 2009). The third C-terminal domain, the PIWI domain, specifies 
the endonuclease or “Slicer” activity of Ago proteins. This domain adopts a folded 
structure that closely resembles the catalytic domain of the Bacillus holodurans 
RNaseH enzyme that carries an Asp-Asp-His (DDH) motif in its active site (Rivas et 
al., 2005). Drosophila has five Argonaute family members (Argonaute1, Argonaute2, 
Argonaute3, Aubergine and Piwi). Drosophila Ago1 has been shown to functionally 
associate with Dicer-1 while Ago2 does so with Dicer-2 (Okamura et al., 2004). These 
correlate with the different roles of Dicers in the maturation of small RNAs as 
described in section 1.2.2.  
 
1.2 Mechanisms of miRNA action 
 
1.2.1 Mechanism of miRNA action 
 
In the RISC, the miRNA/siRNA act as guide molecules by targeting mRNAs based on 
their sequence complementarity. siRNAs generally bind to their mRNA targets by 
perfect pairing, which then directly lead to mRNA cleavage by Ago slicer activity. 
Animal miRNAs use distinct modes of target repression due to imperfect base pairing 
of miRNA sequences with the target mRNA, leading to mRNA destabilization or 
inhibition of protein translation.  
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1.2.2 Effects on target mRNA level 
 
1.2.2.1 Direct mRNA cleavage 
 
When a region in the target mRNA has perfect complementarity with the small RNA, 
the RISC cleaves the target mRNA between residue positions 10 and 11 from the 5’ 
end of the corresponding small RNA. This cleavage is catalyzed by the PIWI domain 
of a subclass of Argonaute protein (like Ago2 in Drosophila). The resulting cleavage 
products are degraded by the exosome in the cytoplasm. A miRNA RISC complex 
could become competent for target cleavage if the target mRNA has perfect 
complementarity with the miRNA, ie, the miRNA and siRNA function is 
interchangeable depending on the extent of base pairing with the target mRNA. This is 
supported by the fact that an endogenous miRNA can mediate cleavage of a reporter 
containing perfect complementary sites in its sequence; on the other hand, an 
exogenous siRNA does not cleave a target if the sequences are not complementary 
(Doench et al., 2003; Hutvagner and Zamore, 2002). It is notable that most of the 
miRNAs in plants have near perfect complementarity with either the coding region or 
the 3’ untranslated region (3’UTR) of the target mRNA and target mRNA cleavage by 
miRNA is the predominant mechanism. The miRNAs in animals usually bind to target 
mRNA via imperfect complementarity in the 3’UTRs or coding sequences and thus 
direct target cleavage is relatively rare.  
 
1.2.2.2 Repression by mRNA destabilization 
 
One predominant mechanism by which animal miRNAs act on their targets is by 
promoting mRNA destabilization (reviewed in (Bartel, 2009)). This is supported by 
the following experimental observations. (1) microarray profiling of change in mRNA 
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levels upon miRNA overexpression or depletion largely correlated well with 
quantitative proteomic change upon miRNA misexpression ((Baek et al., 2008; Guo et 
al., 2010a; Selbach et al., 2008). (2) The ribosome profiling method used RNA 
sequencing of ribosome-protected mRNA fragments (RPFs) to directly compare the 
density of ribosomes on mRNAs with mRNA abundances. This allowed direct 
comparison of effects of miRNAs on both transcript levels and translational efficiency 
at a particular time point. This study suggested majority of targets (>80%) are 
regulated by miRNAs primarily at mRNA level (Guo et al., 2010a). (3) Mechanistic 
studies use in vitro biochemical assay suggested that miRNAs recruit Ago/GW182 
complexes to the target site, leading to the recruitment of decapping enzymes and  
deadenylation enzymes to initiate mRNA degradation program (Behm-Ansmant et al., 
2006a).  In summary, it appears miRNA-mediated target repression acts mainly by 
decreasing mRNA levels.  
 
GW182 protein has been shown to be critical for miRNA-mediated mRNA 
destabilization. Two domains of GW182 proteins are shown to be critical in silencing. 
One is the N-terminal domain containing multiple GW repeats, which is responsible 
for binding to Argonaute proteins and RISC effector complex assembly (Behm-
Ansmant et al., 2006a). The other is a bipartite middle and C-terminal silencing 
domain, separated by a putative RNA recognition domain (RRM). Deletion of either 
the middle or the C-terminal GW-repeat regions of Drosophila GW182 impaired 
silencing activity and depletion of both domains completely abolished silencing 
(Eulalio et al., 2009a). GW182 promotes mRNA degradation by recruiting decapping 
enzymes like DCP1 and DCP2 as well as the deadnylase complex CAF1-CCR4-NOT1 
(Eulalio et al., 2009b). The loss of the cap and poly(A) leads to destabilization of the 
mRNA and recognition by exonuclease Xrn1 to accelerate the 5’-3’ degradation of the 
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mRNA (Giraldez et al., 2006b; Rehwinkel et al., 2006a). A graphic representation of 
Ago/GW182 action on miRNA/mRNA is shown in Fig 1.3   
1.2.3 Effect on protein translation 
 
Though majority of targets (>80%) might be regulated by miRNAs primarily at 
mRNA level, there are examples of targets repressed during protein translation without 
involving much change in mRNA (Behm-Ansmant et al., 2006a; Guo et al., 2010b). 
Substantial studies have been carried out to examine which steps of protein translation 
are affected by miRNAs. There are thee majority steps during protein translation: 
initiation, elongation and termination. Each of these stages requires multiple protein 
factors for execution. Intuitively, the optimum stage to be controlled for effective 
translation would be initiation since it is the rate-limiting step. Most of the cellular 
mRNAs require a 5’ terminal m7G cap and an intact polyadenylated tail for effective 
translation. 
 
Analysis of the polysome profile of luciferase reporters which were repressed by 
endogenous let-7 or miRNA-independent tethering of Ago1 to the reporter showed a 
shift of the repressed mRNA towards the lighter fractions of a sucrose gradient. This 
effect indicates an effect at the initiation step of translation (Pillai et al., 2005). Similar 
observations were made with cationic amino acid transporter 1 (CAT-1) mRNA and 
miR-122 in liver and hepatoma cell cultures (Bhattacharyya et al., 2006). These and 
other experiments suggest that the miRNA might affect an early step of initiation, 
which involves the m7G cap recognition and the requirement of a poly-A tail.  
 
Some other studies instead suggested the repression may happen post initiation. 
Evidence for this model has been obtained in both C. elegans and mammalian cell 
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cultures. The lin-4 miRNA represses the translation of lin-14 and lin-28 mRNAs, both 
of which encode two heterochronic regulators in C. elegans. Analysis of sucrose 
gradients and metrizimide-buoyant density gradients of these mRNAs remained 
unchanged in conditions of repression suggesting that the mRNAs are successfully 
loaded on to ribosomes for translation (Seggerson et al., 2002). Similar results were 
obtained in mammalian cell cultures indicating the possibility of repression at a stage 
post initiation (Petersen et al., 2006). These observations were explained by a 
ribosome drop-off model in which the ribosome falls off the target mRNA while still 
translating, resulting in premature termination. Hence, the mode of miRNA-mediated 
target repression could be rather complex, involving multiple mechanisms at mRNA 
and/or protein translation level.  
 
1.4 Identification and validation of miRNA targets 
1.4.1 Identification of miRNA targets 
1.4.1.1  Computational prediction 
 
Computational prediction methods have been instrumental in target identification. 
Some of the most frequently used ones are TargetScan, Pictar, miRanda, mirWIP, 
PITA and MinoTar. Seed match and evolutionary conservation have been common 
among the majority of prediction algorithms, while other parameters, like hybrid 
energy, site accessibility and UTR context features varied from one to another.   
 
Table 1.1 summarizes and compares the weightage of different parameters 
implemented in various algorithms.  Numbers of “+” represent the weighting for each 
parameter implemented in a given algorithm. (1) Seed match. Initially based on 
systematic mutational study on microRNA sequences and target reporter assays, and 
later supported by elegant structural proofs, demonstrated the importance of 
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microRNA 5’ seed region, a 6-7 nucleotide fragments starting from position 2, in 
target recognition (Brennecke et al., 2005b; Doench and Sharp, 2004a; Kiriakidou et 
al., 2004; Kloosterman et al., 2004; Lewis et al., 2003). Minotar and TargetScan 
require an exact 7-8 base pair match at miRNA seed region while the others allow 
mismatches and/or G:U base-pairing to different extents (Friedman et al., 2009; Lewis 
et al., 2005; Lewis et al., 2003; Schnall-Levin et al., 2010) .  
 
(2) Evolutionary conservation. All the algorithms emphasize evolutionary conservation 
except for mirWIP that is only based on alignments of 2 distant C elegans species 
(Hammell et al., 2008b).  
 
(3) Hybrid energy and site accessibility. The hybrid energy (ΔG) is the energy gained 
during miRNA-target pairing, which is a measurement of duplex stability. It is 
relatively intuitive to expect that the stronger hybrid energy it is, the more stable 
binding it should be. This perhaps also implies a higher number of base pairs in a 
given miRNA binding site. The majority of programs utilized this feature for 
predictions. Some programs, like mirWIP and PITA, further developed a calculation 
for total energy or interaction energy, which measures the differences between the free 
energy gained by the binding of the microRNA to the target and the energy required to 
open local RNA structure either flanking or within the binding sites (Hammell et al., 
2008b; Kertesz et al., 2007a). The total energy (ΔΔG) is a measurement of the 
possibility that how likely a local structure is open.  
 
Different from other prediction programs, mirWIP used machine-learning algorithms 
based on features enriched in the mRNA targets recovered from AIN-1 and AIN-2 
(GW182 family proteins) immunopurification in C elegans. Among the enriched 
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parameters including seed match, hybrid energy and structural accessibility, the 
authors found a window of 25 nucleotides upstream of the miRNA binding sites are 
structurally much more accessible in immunopurified miRNA targets, which 
correlated very well with the calculated total interaction energy (ΔΔG).  With the large 
amount of mRNA training data came from IP, it is shown that mirWIP outperforms 
other popular prediction softwares including Targetscan, miRanda, PITA, PicTar and 
rna22 in recovering validated miRNA targets and rejecting all false positive Lsy-6 
targets in C elegans (Hammell et al., 2008b). It would be quite interesting to further 
apply this machine-learning algorithm to other model system once more genome-wide 
miRNA-target interaction data based on wet lab experiments are becoming available.    
 
(4) Consideration outside 3’UTR. Prediction at open reading frame (ORF) and 5’UTR 
was overlooked until recently, but is now gaining considerable attention (Table 1). 
One important technical difficulty in predicting ORF sites is that the coding region is 
already highly conserved due to strong selection at the amino acid sequence level. The 
selective pressure from protein level could greatly confound the analysis on 
conservation patterns of miRNA targeting sequences, which is solely at nucleotide 
level. The Burger and Perrimon labs thus developed an algorithm called miRNA ORFs 
Targets (MinoTar) to circumvent this obstacle (Schnall-Levin et al., 2010). Briefly, a 
background conservation rate of all amino acid codons and partial codons was 
calculated based on multi-species alignment. A conservation score was then applied to 
any K-mer sequences within the coding region conditioned on the observed 
background conservation at protein level. A similar approach was used for prediction 
of targets in 5’UTR. Using this algorithm, the authors found that in Drosophila, 
miRNA targeting on ORF is as abundant as in 3’UTR. The prediction is further 
supported by a few experimental validations for predicted ORF targets (Schnall-Levin 
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et al., 2010). Examples of miRNAs targeting at ORFs are emerging by studies from 
other groups (eg, (Herranz et al., 2012a; Ott et al., 2011; Schnall-Levin et al., 2011)     
 
1.4.1.2 Target identification based on genome-wide expression profiling     
 
One unbiased genome-wide experimental approach to identify miRNA targets is to 
misexpress a miRNA of interest in cells/tissues (either overexpression or depletion) 
followed by mRNA profiling. Change in target mRNA level is a reliable readout for 
miRNA activity because studies suggested that miRNAs predominantly affect target 
mRNA stability and mRNA level change correlated well with proteomic change upon 
miRNA misexpression ((Baek et al., 2008; Guo et al., 2010a; Selbach et al., 2008). 
mRNA expression profiling has been a powerful tool to identify target genes of many 
miRNAs such as mir-1, mir-124 and mir-200 family (Grimson et al., 2007a; Karres et 
al., 2007; Lim et al., 2005; Park et al., 2008). Recent technological development on 
next-generation RNA sequencing might provide more comprehensive quantification of 
mRNA copy number change than microarray (Xu et al., 2010). 
 
Though majority of target mRNA changes correlated well with changes in protein 
level, there are well-documented evidences of certain miRNA targets that change 
mainly at protein level (Behm-Ansmant et al., 2006a).  Therefore measurement of 
target protein level by quantitative proteomics could be a precise measurement of 
miRNA action on its targets and perhaps also reveal crucial changes in pathway 
activity caused by a miRNA.  
 
One popular strategy to achieve high-resolution proteomic quantification is the stable 
isotope labeling by amino acids in cell culture (SILAC). Briefly, the same cell types 
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firstly grow in normal medium (“light” medium, L). After miRNA overexpression or 
depletion by transfection, the control group (mock transfection) and treated group are 
shifted to growth medium either containing heavy amino acids (“Heavy” medium, H) 
or “medium-heavy” amino acids (M), respectively. The non-radio active stable 
isotopes are incorporated only in specific essential amino acids. For examples, in the 
study by Selbach et al., the “light” medium contains non-labeled L-lysine 
monohydrochloride and L-arginine monohydrochloride; The “medium-heavy” 
medium contains “Lys4”, the 4,4,5,5-D4-L-lysine monohydrochloride and “Arg6”, the 
L-arginine-C monohydrochloride; “Heavy” medium refer to the amino acid “Lys8”, L-
lysine-13C6 15N2 monohydrochloride and “Arg10”, L-arginine-13C6 15N4 
monohydrochloride (Sigma-Aldrich, (Selbach et al., 2008)). After a short period of 
incubation (24 hours), the cells are harvested and combined from both groups for 
subsequent trypsin digestion, reversed phase liquid chromatography (LC) and mass 
spectrometry (MS). Tryptic digestion cleaves C-terminal of Lysine and Arginine, 
leaving a peptide signature, belonging to either “L”, “M”, or “H” of lysine or arginine 
residues. The shift in molecular mass of either 8 Da (between L and H) or 4 Da 
(between L and M) can be detected by MS. The ratio between H and M presumably 
reflects changes in global protein production upon miRNA treatment as compared to 
mock transfection.  
 
Both mRNA microarray and SILAC quantification provide powerful means to identify 
potential miRNA targets, yet there are complications from these two methods. One 
major caveat is the artifacts caused by miRNA overexpression. Overexpression of a 
miRNA to a non-physiological level would cause repression of some targets that is 
normally not regulatable by the miRNA; furthermore, the endogenous Ago complex 
might also be saturated by the ectopically expressed miRNA and thus becoming not 
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available for other endogenous miRNAs. This could lead to derepression of target 
genes for other endogenous miRNA that might confound analysis (Khan et al., 2009). 
Hence, ideally it would be more effective to deplete the endogenous microRNA and 
monitor the upregulation of its targets given the miRNA of interest is expressed at 
considerable level. Another potential complication is that the genes downregulated by 
miRNA overexpression or upreuglated upon miRNA depletion based on microarray or 
SILAC techniques are a mixture of direct and indirect targets.  
 
1.4.1.3 Biochemical purification of miRNP complex coupled to high throughput 
platforms 
 
Computational predictions suggest potential miRNA-target interactions without prior 
experimental evidence. More importantly, most of current major prediction programs 
do not consider whether the miRNA and targets are co-expressed in the same cell 
types, which is a prerequisite for miRNAs to bind to their targets. While expression 
profiling is effective for identifying target gene expression change, it needs additional 
steps, usually aided by computational analysis like seed match, to filter out any 
secondary targets.  
 
To overcome these limitations, direct immunopurification (IP) of Ago/GW182 
complex coupled to mRNA array/RNA-sequencing platforms could be an effective 
way to address the physiological interactions between miRNAs and their targets within 
the RISC effector complex.  Antibodies against the effector proteins, either Ago or 
GW182, can be used to IP Ago/miRNA/mRNA complex from cells upon lysis 
(Beitzinger et al., 2007; Easow et al., 2007; Hendrickson et al., 2008; Hong et al., 
2009; Karginov et al., 2007a). Salt concentrations in wash buffer and number of wash 
steps are important determinants of IP recovery efficiency (Hong et al., 2009). One 
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major problem of the direct IP method is that it may not recover all potential targets 
that interact with miRNAs. This might be due to the fact that majority of target 
mRNAs are destabilized by mRNA decapping and deadenylation enzymes upon 
miRNA binding (Behm-Ansmant et al., 2006), which suggests the association between 
a miRNA and its targets could be transient and very sensitive to stringency of wash 
conditions. Another potential problem is the observations that RNA binding proteins 
and the RNA substrates could form artificial complexes post cell lysis (including 
Ago/miRNA/mRNA complex) (Mili and Steitz, 2004; Riley et al., 2012), creating non-
physiological interactions during IP.   
 
To circumvent these limitations, cross-linking coupled with immunoprecipitation 
(CLIP) is employed for identification of miRNA binding sites. The CLIP methods 
coupled to next-generation RNA sequencing (CLIP-seq) greatly improves the 
detection sensitivity and specificity, as compared to conventional IP. The first example 
of Ago CLIP-seq is called high-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation (HITS-CLIP), which is carried out in P13 mouse 
brain (Chi et al., 2009). HITS-CLIP uses short wave UV irradiation at 254 nm to 
generate a covalent bond between RNAs and proteins in mouse brain homogenates, 
which then allow stringent wash steps for highly purified Ago/miRNA complex using 
antibody against Ago. After RNase treatment and linker ligation on both ends of Ago-
associated RNA fragments, the RNAs are then subjected to cDNA synthesis and next-
generation sequencing. In this way the authors identified ~500 Ago-associated 
miRNAs as well as ~800 transcripts, that are highly enriched for 6-8 nt motifs 
complementary to associated miRNA seed sequences (Chi et al., 2009). The same 
technologies have been successfully applied to study Ago/miRNA/mRNA interactions 
in other organism or tissues. Other groups subsequently developed an improved 
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crosslinking method named photoactivatable-ribonucleoside-enhanced crosslinking 
and immunoprecipitation (PAR-CLIP). Cells are incubated with photoactivatable 4-
thiouridine. This improves RNA recovery by 100- to 1000-fold compared to the HITS-
CLIP methodology and is capable of identifying the location of the crosslinking and 
thus more precisely indicate the site of targeting. This is achieved by the fact that 4-
thiouridine incorporation into RNA during co-incubation in cell culture could result in 
thymidine (T) to cytidine (C) transitions (Hafner et al., 2010). 
 
Fig 1.4 summarizes common strategies used for identification of miRNA targets. A 
combinatorial usage of these methods could generate the overlapping sets of genes that 
are identified by more than one method. Narrowing down target list for further 
validation could result in higher chance of finding bona fide targets. 
 
1.4.2  Experimental validation of microRNA targets 
 
While the methods used in section 1.4.1 could potentially provide a comprehensive list 
of potential microRNA targets, they do not tell whether these potential targets are 
directly regulated by microRNAs. Nor do they tell whether the regulation of these 
targets is functionally important in a given physiological context. Therefore, it is 
important to validate whether a target is directly regulatable by the microRNA and to 
provide substantial functional evidence for a particular microRNA-target interaction in 
a given biological context.   
 
1.4.2.1  Target reporter assay in vitro and in vivo  
 
A reporter assay system typically consists of the reporter gene, which produces a 
reporter protein like GFP or luciferase with the 3’ end fused to a 3’UTR sequence 
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containing candidate microRNA binding sites. The microRNA of interest is often co-
expressed together with the reporter. Given the fact that microRNAs could target 
protein coding regions or 5’ UTRs, one can also engineer the site sequences into the 
open reading frame or 5’ UTR of the reporter gene to mimic the targeting location in 
vivo (Hafner et al., 2010; Schnall-Levin et al., 2010). In order to demonstrate the 
importance of microRNA-target base pairing, the predicted sites, particularly the 
nucleotides targeted by microRNA seed region, is mutated to disrupt the binding. It 
has been shown that one single base mutation at microRNA seed pairing region could 
significantly affect targeting efficiency (Brennecke et al., 2005b). However, if there 
are strong base pairing between the target and miRNA 3’ region, which provides 
supplemental support, one might need to deplete more than 1 nucleotide at seed site in 
order to see significant change in repression.  The repressive effect of the miRNA is 
expected to be significantly dampened in the reporter construct with the binding site 
mutated. For cell-based reporter assays, a second reporter lacking miRNA binding 
sites is generally employed to monitor transfection control (Brennecke et al., 2005b; 
Doench and Sharp, 2004a). 
 
While cell-based assays are convenient to use and widely applicable for a variety of 
cell types, genetic manipulation of microRNA and target interaction in vivo is possible. 
The microRNA and/or wildtype and mutant target sequence transgenes could be co-
expressed in vivo, and the reporter expression (eg. GFP) could be visualized and 
quantified at the single cell level by microscopy (Brennecke et al., 2003b; Brennecke 
et al., 2005b; Johnston and Hobert, 2003). The tissue-specific expression of microRNA 
and target allow comparison between cells expressing both the microRNA and target 
versus adjacent cells, which express the reporter alone. However, although it is 
elegant, the in vivo experimental validation could be time-consuming and labor-
	   17	  
intensive when applied to higher organisms like mammals. The in vitro and/or in vivo 
reporter assay demonstrating that a microRNA regulates an mRNA sequence in a site-
dependent manner provides crucial evidence for functional microRNA-target 
interactions.    
1.4.2.2 Measuring target level in microRNA overexpressed and/or depleted cells  	  
 
The heterologous system described above is important to reveal a functional 
microRNA site, but it is not guaranteed that these interactions are physiologically 
important in a given context in vivo. microRNAs have the potential to regulate up to 
hundreds of targets, however, it might be only few of these targets are regulated to a 
meaningful extent by the microRNA in a particular cell type. It has been shown that 
the target mRNAs correlated well with proteome change upon microRNA 
misexpression (Baek et al., 2008; Selbach et al., 2008) and more than 80% of 
microRNA-mediated target repression is due to mRNA degradation as shown by 
polysomal profiling (Guo et al., 2010a). Therefore, for most of cases, the mRNA levels 
of a target could be a good indicator of regulation by miRNAs. The mRNA expression 
change could be accurately quantified using real-time quantitative PCR system based 
on cDNA copy number in microRNA overexpressed or depleted cells. For those 
targets that do not have obvious changes in mRNA levels, conventional immunoblot 
analysis could be used to detect changes at protein level if a good antibody is 
available. In theory, if the miRNA and target interactions happen at endogenous level, 
by manipulating the microRNA level, either overexpression or depletion, one should 
see a corresponding change of the target mRNA and/or protein.  
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1.4.2.3 Genetic and functional interactions between a microRNA and its targets 
 
Demonstrating the interaction between microRNAs and targets at the molecular level 
is a crucial first step, but it does not address the functional importance of this 
interaction in vivo. microRNAs have been shown to play critical roles on many aspects 
of biology and changes in microRNA levels have substantial influence on the 
organism’s survival and behavior. To reveal whether a particular target plays a 
significant role in microRNA-mediated biological function, simultaneous manipulation 
of the microRNA and target levels becomes essential. If a microRNA loss-of-function 
phenotype (LOF) is mainly caused by upregulation of one or few targets, reduction of 
those targets in the miRNA LOF cells should be able to rescue the abnormality. Vice 
versa, if a miRNA gain-of-function phenotype (GOF) is caused by reduction in targets 
levels, re-expression of these targets in miRNA overexpressing cells should be able to 
reverse the phenotypic change caused by miRNA overexpression. These effects should 
be well recapitulated by tissue or cell type-specific depletion of miRNA by sponges or 
conditional knockout.  
 
Computational prediction suggests that each miRNA could have up to hundreds of 
targets, hence one microRNA may act on multiple targets to regulate a biological 
process in vivo. It is relatively straightforward to manipulate several targets together 
with the miRNA in vitro by cotransfection in cells, however, genetically introducing 
many target transgenes at the same time in vivo could be challenging. Nevertheless, 
concurrent targeting of multiple targets by one or few miRNAs to maintain or confer 
the robustness of a regulatory network have been postulated and supported by 
emerging studies (Li et al., 2009; Tsang et al., 2010) 
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1.5 Genetic manipulations of miRNA activities in cells and organisms 
 
In order to understand how a miRNA works in a cell or organism, experimental 
manipulations of miRNA expression by genetic and/or molecular tools are critical to 
gain functional insights.  	  
1.5.1 Genetic knockouts 
 
Functional loss of miRNA activities in different model organisms has shown to exert 
distinct impact on the organism’s viability and development. While most of individual 
microRNA deletions in C elegans is reported to neither affect the animal’s survival nor 
cause much phenotypic abnormality, a number of microRNA knockout mutant in flies 
and mice have shown defects in development, survival or behavior (Brennecke et al., 
2003b; Hilgers et al., 2010; Karres et al., 2007; Klein et al., 2010; Miska et al., 2007b; 
Poy et al., 2009; Rasmussen et al., 2010; Sokol et al., 2008; Teleman et al., 2006; 
Varghese and Cohen, 2007b; Ventura et al., 2008; Wang et al., 2008a; Zhao et al., 
2007). Genetic knockout of a microRNA ensures complete loss of miRNA activity in 
an intact animal and provides the most direct way to assess miRNA functions in vivo. 
Forward genetic screen using chemical mutagen or transposon-mediated mutagenesis 
have identified a number of miRNA mutants in C elegans and Drosophila (Abbott et 
al., 2005; Lee et al., 1993; Li and Carthew, 2005; Wightman et al., 1993; Xu et al., 
2003). While being effective, the mutant alleles generated by these methods may not 
be null and could potentially affect other unrelated DNA sequences nearby the miRNA 
locus. A large fraction of miRNAs locate in the intronic regions of protein-coding 
genes, hence a precise deletion of DNA sequences covering only the miRNA locus 
without much effect on the host gene is required for a clean knockout (review in (Li et 
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al., 2007). Targeted gene deletion based on homologous recombination has been 
successfully applied to a few model organisms including yeast, mouse and recently in 
Drosophila (Rong et al., 2011; Rong and Golic, 2000, 2001, 2003).   
 
The ends-out homologous recombination method has been utilized by our group for 
generating microRNA knockouts (Chen et al., 2011; Ge et al., 2012; Hilgers et al., 
2010; Weng et al., 2009). Fig 1.5 shows a schematic representation of the knockout 
strategy. Briefly, a P-element based FRT targeting construct (pw25 vector) is designed 
to contain two homology arms followed by I-SceI meganuclease cutting site and FRT 
sequences. The mini-white gene, which is used to replace the miRNA sequences and 
also used as a marker for selection, is placed in the centre of two arms. Two LoxP sites 
are engineered to flank the mini-white gene, which could be used to flip out the mini-
white gene by the Cre recombinase (Siegal and Hartl, 1996). Each homology arm is 
designed to be about 3.5-4kb in length, and identical to upstream and downstream 
flanking sequences of the miRNA locus in Drosophila genome, respectively. By P 
element-mediated transformation, a transgenic donor line is generated based on eye 
color: those flies with successful integration of mini-white gene will in principle have 
red eye. Upon expression of FLP recombinases and I-SceI nuclease, the targeting 
construct will be excised from the integration locus and released as an extra 
chromosomal linear DNA molecule, which could then undergo homologous 
recombination with the miRNA locus. Eventually, the endogenous miRNA locus will 
be replaced by the targeting construct containing the mini-white gene.  
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1.5.2 Application of miRNA sponges 	  
 
Making a miRNA knockout in Drosophila typically takes 4-5 months, and even longer 
for mouse knockouts. A significant portion of knockout flies for certain miRNAs are 
lethal or semi-lethal during development, thus the assessment of miRNA functions in 
adult tissues is not feasible in these mutants (Chen YW et al., unpublished 
observation). Therefore, a method that can create tissue-specific depletion of miRNA 
activities at any developmental stages would greatly complement the knockout study 
and could even reveal phenotypes in certain tissues/cells that may not be possible in 
whole-animal knockouts.  
 
MicroRNA sponges offer great advantages and broad applicability in studying 
microRNA functions in vitro and in vivo. A sponge is a transcribed artificial RNA 
sequence containing multiple consecutive binding sites for one microRNA or the 
whole microRNA family, as defined by identical seed sequences (miRNA 5’ 
nucleotide position 2-8) of the microRNA. A sponge sequence is typically designed to 
contain 5-10 repeated sequences that are complementary to the mature microRNA, 
either perfectly match or there is a central mismatch for 3-5 nucleotides, which forms a 
bulge to prevent direct cleavage by Ago proteins. When these sponge RNAs get 
expressed, they presumably sequester microRNAs upon binding, thus prevent targeting 
on the endogenous mRNAs. This creates a microRNA loss-of-function status in certain 
cells or tissues, depending on which promoters being used to drive the sponge 
expression. A reporter, like GFP or dsRed, is typically used in the sponge construct to 
monitor sponge expression. As compared to genetic knockouts, the sponge sequence is 
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relatively convenient to be introduced to cells or organisms by transient transfection or 
integration into the genome using various gene transfer tools. 
 
Fig 1.6 is a demonstration of miRNA sponge design. A UAS-microRNA-sponge 
transgene is generated to deplete miRNA activity in vivo using Gal4/UAS regulatory 
system. The sponge consists of a P element-based UAS transgene that contains ten 
microRNA binding sites downstream of GFP coding sequence. The GFP sequence 
could be used to estimate the expression level of sponge RNA. A polyA tail is added at 
the end of sequence followed by mini-white transgene. The sponge sequence is 
complementary to the microRNA mature sequence except the center 3-4 nucleotides. 
A transgenic fly is generated to carry the UAS-microRNA-sponge by P element-
mediated transformation. Upon expression of the sponge sequence by crossing the 
UAS-microRNA-sponge with a Gal4 line, the sponge RNA should form a stable 
pairing with the mature miRNA. Because of the central 3-4 nucleotides bulge, 
cleavage of the sponge sequence by Ago catalytic activity will be prevented. The 
beauty of using binary Gal4/UAS system for miRNA sponge expression is that one can 
study miRNA loss-of –function in a temporally and spatially controlled manner, 
allowing high resolution assessment of phenotypic outcome in any tissues/cells for a 
certain developmental stage. Others and we have successfully used the sponge system 
to study miRNA functions in Drosophila (Becam et al., 2011; Herranz et al., 2012a; 
Herranz et al., 2012b; Loya et al., 2009). An example of microRNA sponge 
application used in this thesis is fully demonstrated in Section 4.1.  
 
The application of miRNA sponge in vertebrate system are also well demonstrated in 
many studies (reviewed in (Ebert and Sharp, 2010). For transient transfection of 
miRNA sponge in mammalian cells, one might use CMV promoter for the sponge 
	   23	  
construct in order to achieve maximum expression of the sponge sequences (Elcheva et 
al., 2009; Rybak et al., 2008). For viral-mediated transduction, a high-titre viral dosage 
is recommended for multi-copy integration of sponge transgene. The advantage of 
using retroviral, lentiviral or adenoviral tools is that one can make stable transgenic 
lines to assess miRNA function over a long period of time both in vitro and in vivo.  
 
Although sponges are versatile tools for studying miRNA functions, they do have 
certain limitations. Firstly, one needs to carefully assess the effectiveness of the 
sponge construct. Unlike the genetic knockouts, the effectiveness of sponges depends 
critically both on the expression level of sponge and the miRNA/miRNA family 
expression level. Some miRNAs are highly abundant in certain cells/tissues that a 
partial reduction in miRNA activity by expressing sponge may not be able to reveal 
any phenotype. Therefore, a good reporter system, either constructs containing a know 
target gene reporter or the miRNA sensor reporter is necessary for accurate validation 
of sponge function. Secondly, a stable knockdown of miRNAs by sponge in transgenic 
mammals involves virus-mediated genomic integration, which prevents them from 
being further developed as therapeutics in human patients.   
 
1.6 miRNA dysregulation in cancer cells  	  
miRNAs collectively could regulate up to thousands of targets and the majority genes 
in a transcriptome can be under surveillance by miRNAs. Thus these tiny regulators 
are important gatekeepers for proper functioning of cellular machineries and pathway 
homeostasis. If a disease status of the cell is marked by abnormal changes in cellular 
and molecular activities, then dysfunctions of miRNAs in these cells could be one 
important contributing factor. Indeed, misregulations of miRNA expression have been 
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observed in a variety of human pathological condition including cancer (Croce, 2009). 
Changes in miRNA expression profiles have been documented in many cancer types. 
Strikingly, the miRNA expression signatures in cancer cells could classify distinct 
subtypes/grades of a given cancer type (eg., primary tumours versus aggressive 
metastatic tumors). The usage of a few miRNA genes in cancer type classifications has 
been proven to be more accurate than the complex combinations of subsets of the 
messenger RNA transcriptome, which apparently are much more noisy (Lu et al., 
2005). Therefore, miRNAs are strongly implicated in cancer development. The study 
of miRNA dysregulation in carcinogenesis not only could help in better understanding 
of cancer initiation and progression, but also has important prognostic value in clinical 
settings. The relative small size of these molecules has made them attractive targets for 
therapeutical applications in human diseases. 
 
1.6.1 Genomic copy number alterations of miRNAs in cancer 	  
One mechanism that contributes to functional dysregulation of miRNAs in cancer is 
suspected to be the chromosomal locations of miRNAs in genomic unstable regions. A 
survey of the genomic locus for 186 human miRNAs suggested more than 50% of 
them are located at fragile sites, including minimal regions of loss of heterozygosity, 
minimal regions of amplification, or common breakpoint regions, whose changes are 
highly associated with cancer (Calin et al., 2004). For example, the miRNA cluster 
15a/16-1 is located in a frequently deleted genomic locus, which is found in more than 
50% of chronic B cell lymphocytic leukaemia patient (Calin et al., 2002). Other 
examples include the let-7g/mir-135-1, which is often deleted in a few cancer types; 
the mir-17~92 cluster, that is observed to be amplified in lymphoma; and the mir-26a 
locus, that is amplified in glioblastoma (Huse et al., 2009; Mavrakis et al., 2010; 
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Tagawa and Seto, 2005). Thus, miRNAs can be preferentially targeted by genomic 
rearrangement events, which occur in cancer cells, like deletion, translocation and 
amplification. This might cause misexpression of many miRNAs, which eventually 
lead to dysregulation of many downstream signaling events.     . 
 
1.6.2 Change in transcriptional regulations of miRNAs in cancer 	  
There are several mechanisms utilized by the cancer cells to misregulate miRNAs at 
the transcriptional levels. One way to achieve this is changes in key transcription 
factor activities. Many important oncogenes or tumor suppressive factors encode 
transcription factors like Myc and TP53. miRNAs could be placed under the control of 
these genes and play a critical role in cancer transformation driven by these 
transcription factors. For example, mir-17~92 is regulated by Myc and suppress Myc-
induced apoptosis in a mouse model of B-cell lymphoma ((Mu et al., 2009). Mir-34a, 
which is frequently downregulated in cancer cells, has been shown to be transactivated 
by TP53 and its expression directly contribute to TP53-induced apoptosis program 
(Chang et al., 2007).Another mechanism is change in epigenetic status of the promoter 
regions of miRNAs. Examples include the epigenetic silencing of mir-127 in bladder 
cancer cells and DNA hypermethylation of mir-9-1 promoter in breast cancer 
(Lehmann et al., 2008; Saito et al., 2006). 
 
1.6.3 miRNAs dysregulate many downstream signaling pathways that are 
critically involved in cancer initiation and progression   	  
The versatility of miRNAs to targets multiples genes involved in the same or distinct 
pathways implicates once miRNA activities are misregulated, multiple pathways are 
likely to be affected. Many biologically important pathways involved in cancer, like 
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apoptosis, differentiation, proliferation, migration and stem cell self-renewal, have 
been shown to be targeted by miRNAs. The skeletal muscle-specific miR-206 is 
reported to blocked human rhabdomyosarcoma growth in mouse xenograft models by 
inducing myogenic differentiation ((Taulli et al., 2009). The mir-200 family miRNAs 
target zinc-finger enhancer binding (ZEB) transcription factors to modulate epithelial-
to-mesenchyme transitions in both development and cancer (EMT) (Brabletz and 
Brabletz, 2010). The let-7 miRNA is specifically downregulated in poorly 
differentiated breast cancer cells while re-expression of let-7 miRNAs lead to 
downregulation of H-Ras and HMGA2, which eventually lead to reduced proliferation, 
tumor formation and metastasis (Yu et al., 2007).  
 
In summary, the changes in miRNA activities in a normal cell is likely to perturb the 
homeostasis of multiple pathways, which could be causative for changes in cellular 
behaviors. A further cooperative role of miRNAs with important oncogenic stimuli 
might lead to effective cancer transformation from benign hyperplasia. During cancer 
progression and metastasis, aberrant miRNA activities might facilitate maintenance of 
cancer stem cell self-renewal and distant metastatic capability of cancer cells.   
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Figure 1. 1 microRNA biogenesis and action 
The primary miRNA is generated by RNA polymerase II to form a normal 5’ capped 
and 3’ polyadenylated transcript. The Drosha/Pasha complex cleaves the pri-miRNA 
transcript into a ~60-70 nt stem loop precursor miRNA (pre-miRNA) with a 
5’phosphate and an ~2nt 3’ overhang. The 3’ overhang of the pre-miRNA is 
recognized by Exportin-5, a Ran-GTP dependent nuclear export factor, and exported to 
cytoplasm. The pre-miRNA in cytoplasm is further processed by another RNaseIII 
enzyme complex called Dicer/Loquacious. Dicer recognizes the 3’ 2nt overhang of the 
pre-miRNAs through its PAZ domain, cleaves the pre-miRNA to produce the mature 
miRNA duplex. The RNAi-induced silencing complex (RISC), mainly containing Ago 
and GW protein complex, will preferentially load one of the miRNA strand and pair to 
the target mRNAs. The pairing between miRNA and their target will typically result in 
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Figure 1. 2 Argonaute domain organization  
Argonaute proteins are characterized by the presence of three domains: the PAZ 
domain, the Mid domain and the PIWI domain. The PAZ domain forms a binding 
pocket for the 3′ end of the small RNA, whereas the 5′-terminal nucleotide is bound by 
the Mid domain. The PIWI domain has catalytic endonuclease activity, referred to as 
slicing. The slicer activity allows the Argonaute to degrade one of the strands of the 
dsRNA, thereby exposing the single-stranded RNA and allowing it to detect its target 
by sequence complementarity. Slicer activity is also important for the degradation of 




Figure 1. 3 Ago/GW182 as effector complex in miRNA-mediated gene silencing.  
RISC is represented as a complex minimally including an Argonaute protein (green) 
and GW182 (blue). GW182 proteins contain an N-terminal AGO-binding domain, 
which provides multiple binding sites for Argonaute proteins and a bipartite C-
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terminal silencing domain (SD), which promotes translational repression and decay of 




Figure 1. 4 Methods to identify microRNA targets 
(A). Computational programs give a list of candidate targets that could pair with the 
miRNA of interest. By looking at the overlapped output among different prediction 
methods might help to find real targets. (B) Biochemical approaches that purify the 
preserved miRNA-mRNA pairs within the Ago-GW182 complex with or without 
cross-linking methods could effectively isolate physiological miRNA-target 
interactomes. (C). Expression profiling methods are commonly used to detect 
mRNA/proteome changes upon miRNA overexpression or depletion. If possible, the 
overlapped fraction generated from A, B and C (or any two of them) should reveal real 
miRNA-target interaction at higher confidence. The candidate list could be subject to 
further experimental validations.         
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Figure 1. 5 Schematic representation of ends-out gene targeting by homologous 
recombination 
3.5–4 kb homology sequences flanking the target gene are cloned into the pW25 ends-
out vector. P-element-mediated transformation gives rise to transgenic donor 
containing the targeting cassette. Induction of FLP recombinase is used to excise a 
circular DNA molecule containing the targeting vector, which is then linearized by 
cleavage with the I-SceI meganuclease. The linearized targeting vector can then 
recombine with the chromosomal target locus, replacing the endogenous gene with 
mini-white and generating a mutant heterozygous for the targeted miRNA. Figure 
adapted from (Weng et al., 2009). 
 





Figure 1. 6 miRNA sponge design 
Tissue-specific expression of the Gal4 transcription factor was used to drive miRNA 
sponge expression under the control of upstream activating sequences (UAS) in 
transgenic fruit flies. The sponge consists of a P element-based UAS transgene that 
contains ten microRNA binding sites downstream of eGFP coding sequence. The 
eGFP sequence could be used to estimate the expression level of sponge RNA. The 
sponge sequence is complementary to the microRNA mature sequence except the 
center 3-4 nucleotides. A transgenic fly is generated to carry the UAS-microRNA-
sponge by P element-mediated transformation. By crossing with different Gal4 fly 
lines, the microRNA sponge sequence could be expressed in spatially defined tissues 
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Table 1. 1 A comparison of different computational prediction programs 
A total of six different parameters implemented in the six prediction programs are 
cross-compared and evaluated by the weightage as marker by "+". The more "+" 
represents the higher weighting of the parameter in a given program. The last 
parameter, "consideration of sites outside UTR" is evaluated with either "Yes, Y" or 
"No, N".
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Chapter 2 Materials and methods  
 
2.1 Drosophila genetics 
 
The stocks used are described in the following references: MS1096-Gal4 (Capdevila 
and Guerrero, 1994); ap-Gal4 (Calleja et al., 1996a, b); ptc-Gal4 (Wilder and 
Perrimon, 1995); UAS-EGFR (Buff et al., 1998); UAS-Socs36E (Callus and Mathey-
Prevot, 2002); UAS-bantam-sponge (Becam et al., 2011); UAS-Socs36ERNAi (ID 
number:51821, Vienna Drosophila RNAi Center); UAS-bantam-GFP (Brennecke et 
al., 2003a); UAS-diap1 (Wang et al., 1999); diap-1-lacZ (Hay et al., 1995); Dlg-GFP 




Rat and Rabbit polyclonal antibodies to Socs36E protein were provided by F. Serras 
and used at 1:300 dilution. Other primary antibodies were:  Rabbit anti-Gal4 (Santa 
Cruz Biotechnology); rat anti-DE-cadherin and mouse anti-MMP1 (Developmental 
Studies Hybridoma Bank); mouse anti-dpERK, and rabbit anti-Caspase-3-activated 
(Cell Signaling Technology); mouse anti-SOCS5 (Santa Cruz Biotechnology).  
 
Basic staining procedure: Newly hatched 1st instar larvae were seeded at 50/vial and 
reared at 25 degree. Wing imaginal discs from wandering 3rd instar larvae were 
dissected in chilled PBS. Tissues were fixed in PBS with 4% paraformaldehyde for 20 
min and blocked in PBT with 5% BSA for 1hr at room temperature on a shaker 
machine. Primary antibodes was used at 1:200 to 1:1000 dilutions overnight at 4 
degree. Before 2nd antibody and DAPI labeling, tissues were washed in PBT with 1% 
BSA for 3 times, each 15 minutes. Wing imaginal discs was imaged in mounting 
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medium using a Zeiss LSM700 confocal microscope after washing in PBT overnight 
at 4 degree. 
 
 
2.3 SDS-PAGE and immunoblot analysis 
 
Heat denatured protein samples were run in 10%~12% SDS-PAGE at a constant 
voltage of 100V till the lowest marker (20kDa, Progema) reached the end. The gels 
were then transferred to a nitrocellulose membrane in ice-chilled transfer buffer (25 
mM Tris, 192 mM glycine, 0.025% SDS, 20% methanol) at a constant current of 
200mA/membrane for 50 min. The blocking buffer (5% non-fat dry milk in 1 x PBST 
[137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4⋅2H2O, 2 mM KH2PO4, 0.1% Tween-
20]) was used to block the membrane for 1hour at room temperature. After that, 
primary antibodies were added and incubate overnight at 4C. The next day, the 
membrane was washed by 1XPBST wash buffer for 3 times, each for 15 min before 
addition of HRP-conjugated secondary antibodies. After incubation of secondary 
antibody in blocking buffer for 1.5 hours, the membrane was treated with horseshoe 
peroxidase (Promega) for 2 minutes before detection of chemilluminescence. 
 
2.4 Immunopurification of Ago1/miRNA/mRNA complex from Drosophila S2 
cells 
 
Cultured DrosophilaS2 cells were lysed by dounce homogenizer in lysis buffer: 20 
mM HEPES pH 7.9, 150mM KCl (for lysis) or 200 mM KCl (for wash), 0.5% NP-40, 
5mM DTT, 20% glycerol, 2% complete protease inhibitor cocktail (Roche), and 100 
U/ml RNasin (Promega). Two different antibodies were used for IP. For the 
microarray experiment in Fig 2A, transgenic S2 cells stably expressing 3x Flag-HA 
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tagged Ago1 and untransfected control S2 cells were harvested and 
immunoprecipitated with monoclonal rat anti-HA antibody (Roche cat 
No.11867423001, diluted in 1:200, overnight 4°C).  For other experiments lysates of 
untransfected S2 cells were immunoprecipitated with mouse monoclonal anti-Ago1 
(antibody was kindly provided by Dr Mikiko Siomi). 
 
2.5 UTR reporter constructs and luciferase reporter assays 
 
The following primers were used to construct the 3’UTR reporters:  
1. CG6965 F:	  gatcgccgtgtaattctaga	  GAT	  TAC	  TGA	  GGA	  GCC	  ACC	  GT	  R:	  cgttcgaggtcgactctaga	  CTG	  TTT	  GGT	  CAG	  GTA	  GGT	  GTC	  A	  	  2.	  CG8121	  F:	  gatcgccgtgtaattctaga	  ACC	  ATG	  CCC	  GTG	  GGC	  TAA	  TAA	  R:	  cgttcgaggtcgactctaga	  CGA	  AAA	  TGG	  ACC	  CAA	  CTG	  AAG	  TG	  	  3.	  CG7713	  F:	  gatcgccgtgtaattctaga	  GAA	  CAT	  TGA	  GCT	  GCT	  CAT	  GCC	  AT	  R:	  cgttcgaggtcgactctaga	  CCC	  GTA	  TCC	  AGT	  AGC	  AGT	  AGT	  T	  	  4.	  CG9796	  F:	  gatcgccgtgtaattctaga	  TTT	  ATC	  CGC	  TCC	  TTC	  TAC	  TAA	  GC	  R:	  cgttcgaggtcgactctaga	  CCG	  GAC	  TTA	  CCT	  TCA	  ACA	  TTA	  CA	  	  
5. CG10620 F:	  gatcgccgtgtaattctaga	  GCC	  ACT	  AGA	  CTC	  ACT	  TAG	  ATT	  TCA	  R:	  cgttcgaggtcgactctaga	  CAA	  TTG	  CGG	  TCA	  AGA	  TAT	  TAG	  GAT	  TC	  	  6.	  CG13088	  F:	  gatcgccgtgtaattctaga	  TCG	  AAT	  TCA	  GTC	  CAG	  ACT	  CGT	  AG	  R:	  cgttcgaggtcgactctaga	  GCC	  TAT	  ATT	  TGT	  TGT	  TAC	  ATC	  TGA	  AGC	  	  7.	  CG8010	  F:	  gatcgccgtgtaattctaga	  AGC	  AAC	  AGA	  AGC	  TGG	  GAG	  TCG	  R:	  cgttcgaggtcgactctaga	  TAA	  GAC	  GCC	  CAT	  TGA	  GCC	  CAT	  T	  	  8.	  CG3446	  F:	  gatcgccgtgtaattctaga	  CCT	  AAA	  TCG	  GCC	  TAG	  TTA	  ATG	  GAT	  TA	  R:	  cgttcgaggtcgactctaga	  GCA	  TTT	  CGT	  AGT	  GTT	  TTA	  TGT	  TGT	  GAA	  	  	  9.	  Socs36E	  wiltype	  3’UTR	  reporter	  construct:	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Socs36E-­‐UTR_WT-­‐F:	  GAT	  CGC	  CGT	  GTA	  ATT	  CTA	  GAC	  CAC	  ATA	  ACA	  AAA	  TCG	  CTA	  GCT	  C;	  Socs36E	  UTR_WT-­‐R:	  CGT	  TCG	  AGG	  TCG	  ACT	  CTA	  GAT	  TAC	  GAA	  TAA	  CAG	  CAA	  CCA	  CCT	  AG;	  	  10.	  Socs36E	  mutant	  3’UTR	  reporter	  construct:	  Socs36E	  UTR	  mut-­‐F:	  gatcgccgtgtaattctaga	  GTT	  GTG	  GCA	  CTC	  TTG	  AAA	  GCG	  Socs36E	  UTR_mut-­‐R:	  CGT	  TCG	  AGG	  TCG	  ACT	  CTA	  GAT	  TAC	  GAA	  TAA	  CAG	  CAA	  CCA	  CCT	  AG.	  	  	  Cloning	  site	  is	  Xba	  I.	  	  
3’ UTR assay: the selected miR-184 targets were cloned into a firefly luciferase 
reporter plasmid and expressed by transfection in S2 cells. Cells were treated with 
modified antisense oligonucleotides (Dharmacon, (Horwich and Zamore, 2008b) to 
deplete miR-184 or with a control scrambled oligonucleotide. The expression of the 
reporters measured by comparing firefly luciferase to the renilla luciferase transfection 
control. Luciferase assays were performed 72 hours after transfection.  At least three 
independent transfection experiments were performed, each in triplicates. 
 
2.6 RNA extraction and miRNA/mRNA quantitative real time PCR 
Different tissues or Drosophila S2 cell pellets were collected and kept in 10 ul Serum. 
free S2 cell Media (SFM Gibco) supplemented with L-glutamine on ice. After washing 
with chilled PBS, 1 ml Trizol reagent was added to samples and homogenized by 
syringe. Cell lysate was transferred to Phase Lock Gel-Heavy tubes (Qiagen) and 
incubated for 5 min at room temperature. 200 ul chloroform per 1 ml Trizol reagent 
was added into each tube and vortex rigorously. The mixture was then centrifuged for 
15 minutes at 4 degree at 14000 rpm. The upper aqueous phase was carefully pipette 
out by filter tips and mixed with 1 volume of 70% ethanol. After that, the mixture was 
transferred to RNeasy column tubes (Qiagen) for further purification. On-column 
DNase treatment and RNA purification were performed following the handbook in 
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RNeasy Mini Kit (Qiagen). After final wash, total RNA was dissolved in 30 ul water 
and RNA concentration was measured in Nanodrop. Same amount of total RNA (about 
1 ug RNA) was used for a 20 ul reaction.  
 
Reverse transcription was performed to synthesize the first strand used oligo-dT 
primers and Superscript RT-III (Invitrogen). The reaction was performed in PCR 
cycler following the protocol from Supperscript III kit (Invitrogen). After cDNA 
synthesis, 20 ul cDNA was diluted in 60-80 ul water and used as templates for real-
time quantitative PCR (Q-PCR). For each Q-PCR reaction, 12.5 ul POWER SYBR 
GREEN Master Mix (Applied Biosystems), 1 ul diluted PCR primer mixture (stock in 
6.25µM) and 6 ul DNA template were used to make a 25 ul PCR solution with water. 
Real-time Q-PCR was performed in 96 well-plate using Applied Biosystems 7500 fast 
real-time PCR system. For mRNA Q-PCR, the reference gene GAPDH was used as 
normalization control. For miRNA Q-PCR, Taqman master mix and probe was used 
for reverse transcription and quantitative PCR. Ten nanogram of total RNA was used 
for each miRNA Q-PCR sample and data was normalized to reference gene U27. 
 
 
2.7 Expression profiling  
 
Microarray profiling was performed by the EMBL Gene Core using Affymetrix 
Drosophila 2.0 arrays and analyzed using the online analytical tool carmaweb1.4 
(website address: https://carmaweb.genome.tugraz.at/carma/). Total RNA recovered 
from the three independent IP expeirments was amplified and labeled using standard 
affymetrix protocols for hybridization, washing, and data acquisition (Fluidics station 
400, GeneArray 2500 scanner, Affymetrix Microarray suite version 5.1) parameters 
were within recommended limits. Data were imported into GeneSpring 6 (Silicon 
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Genetics) and normalized using the RMA method. Paired Student’s t Test was 
performed and p-values were adjusted by correcting multiple hypothesis testing using 
the method proposed by Benjamini and Hochberg.  
 
2.8 miRNA Target Site Prediction 
 
Prediction of potential miRNA binding sites for both S2 expressed and all D. 
melanogaster miRNAs was performed similarly to that described for the mirWIP target 
prediction algorithm in C. elegans (Hammell et al., 2008b) with some exceptions: the 
Vienna RNA package (Hofacker et al., 1994) was used to calculate the openness and 
DDG. We used the RNAhyrid algorithm (Rehmsmeier et al., 2004) to identify 
potential miRNA binding sites for all D. melanogaster microRNAs in the 3’UTRs of 
all D. melanogaster transcripts. The same procedure was performed separately for all 
microRNAs in the sister species D. pseudoobscura. We then selected only those 
binding sites that occurred for the same microRNA in orthologous UTRs of D. 
melanogaster and D. pseudoobscura, as “conserved sites,” without requiring alignment 
of the binding site sequences. For the purposes of analyzing the types of seed matches 
in the IP-enriched transcripts, we allowed up to 3 G:U wobble pairs in the seed region 
(opposite microRNA nucleotides 2-8), or a single bulge on the mRNA side of the 
duplex. After noticing that the non-canonical binding sites were not enriched in the IP-
enriched transcripts, we then used stricter seed match requirements for all subsequent 
analysis. Specifically, we followed the rules for functional D. melanogaster binding 
sites outlined in (Brennecke et al., 2005b), such that single bulges on the mRNA side 
were allowed, as well as single G:U wobbles in a 7-mer seed match, or two G:U 
wobbles in an 8-mer, and lastly,  a perfect 6-mer (and any imperfect sites) required 
some pairing at the 3’ end of the duplex.  
	   39	  
 
2.9 Statistical Analysis 
 
For all correlation calculations, Pearson’s r and associated P-value, we used the Statlib 
package of statistical software for the python programming language (freely available 
at http://python-statlib.googlecode.com). The P-values for Pearson’s correlation are 
obtained from a z-score calculation after performing a Fisher transformation of the 
correlation coefficient. We also made use of the Statlib package for all P-values 
calculated using the Kolmogorov-Smirnov test. In all cases, these were two-sided P-
values from a two-sample test. All P-values calculated from the Wilcoxon test (also 
known as the Wilcoxon-Mann-Whitney U test) were calculated directly in order to 
properly account for any ties in the ranked lists, but did make use of the Statlib 
package for z-score transformations. All of the above tests are non-parametric, which 
do not require a test for normality. For the special case of shifts in the distribution of 
UTR lengths, we applied a Bonferroni correction to the Wilcoxon P-values because 
this statistical test was repeatedly performed against multiple control groups in search 
of any significant shifts.  
 
2.10 Mammalian cell culture 
 
Cells were grown in DMEM containing 10% FCS. Human primary BJ fibroblasts were 
genetically modified with retrovirally transduced p53 shRNA, p16INK4A shRNA, small 
T antigen, inducible RasV12-ERTAM and hTERT to confer immortality and inducible 
colony formation as described (Acloque et al., 2009). Retrovirus was made by 
calcium-phosphate transduction of Eco-Pack 2 (Clontech) and harvested 20 hours 
later. BJ cells were selected with blasticidin-selective medium 48 hours after 
transduction for 4-6 days.  
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2.11 Soft agar colony formation assay 
 
Cells were resuspended in DMEM medium containing 0.4% low-melting agarose 
(Sigma, type VII) and 10% FCS and seeded onto a coating of 1% low-melting agarose 
in DMEM containing 10% FCS in 6-well culture dishes. After 2-3 weeks of growth (2 
weeks for Tamoxifen treatment and 3 weeks for EGF treatment), plates were stained 
using MTT assay, photographed under identical settings, and colony number was 
scored using Mat-lab 2001b.    
2.12 Cancer patient survival analysis 
 
Two groups of breast cancer patient datasets were used for analysis. For the first group 
(Dataset-1), array sets containing 295 breast cancer samples from Netherland Cancer 
Institute (NKI) were extracted and analyzed as described in (Stuart and Sellers, 2009). 
The second group (Dataset-2), comprises four independent breast cancer expression 
profiling datasets, including a total of 695 primary tumor samples which were pooled 
and annotated with respective clinical information (Supplemental Table 4 for complete 
references to the datasets). SOCS5 status was defined as “SOCS5 High”, SOCS5 
expression higher than the median (median definition) or higher than the third quartile 
(quarter definition) and “SOCS5 Low”, SOCS5 expression lower than the median or 
lower than the first quartile. SOCS5 status was defined separately for the four datasets, 
to allow for possible differences in normalization between them and then pooled for 
analysis. Clinical outcomes were censored at 12 years. Kaplan-Meier analyses were 
performed using the R statistical package. P values were estimated by the log-ranked 
test. The same definitions for SOCS5 status were applied for both datasets. This set of 
computational and statistical analysis were carried out by my collaborator, Dr Zhang 
Rui.  
	   41	  
 
 
Chapter 3 Biochemical purification of miRNA-RISC complex coupled to high-
throughput microarray profiling identifies a distinct set of miRNA targets in 




Animal genomes contain up to thousands of microRNAs, compromising 1-3% of 
genes in Drosophila and C elegans and 2-4% of genes in mouse and human (miRBase 
19). Functional studies on individual miRNAs in vivo have just emerged and the 
majority of these small RNAs remain to be explored (Bartel, 2009; Bushati and Cohen, 
2007; Miska et al., 2007a). The bottleneck of miRNA functional study is to identify 
which mRNA targets that it regulates. Computational approaches have been 
instrumental in target identification. Seed match appears to be a common feature of 
different computational algorithms. However, other contextual features, like hybrid 
energy, binding site accessibility, and UTR composition have also been shown to play 
a role in target recognition. Various prediction programs make use of contextual 
features differently (e.g. (Hammell et al., 2008a; Kertesz et al., 2007b; Kheradpour et 
al., 2007; Krek et al., 2005; Lewis et al., 2005; Stark et al., 2005). 
 
Accumulating evidence suggests each miRNA could regulate up to hundreds of 
targets. miRNA overexpression in heterologous cell types could repress hundreds of 
target mRNA levels (e.g. (Lim et al., 2005). Conversely, depletion of miRNAs results 
in upregulation of hundreds of mRNAs (Eulalio et al., 2007b; Rehwinkel et al., 
2006b). Target mRNAs are destabilized and degraded upon miRNA overexpression 
due to recruitment of mRNA decapping and deadenylation enzymes by the miRNA-
RISC complex, (Behm-Ansmant et al., 2006b; Eulalio et al., 2009b; Giraldez et al., 
2006a). Whole proteome profiling of target protein change upon misexpression of 
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individual miRNAs have demonstrated a tight correlation between miRNAs and 
targets (Baek et al., 2008; Selbach et al., 2008). However, there is well-documented 
evidence that certain targets mainly change at the protein level but not the mRNA level 
(Baek et al., 2008; Behm-Ansmant et al., 2006b; Selbach et al., 2008). Furthermore, 
expression profiles based on target level change contain a mixture of primary targets, 
which are directly regulated by miRNAs, as well as secondary targets that are 
indirectly regulated by miRNAs. Hence, alternative methods for target identification 
are needed to complement the limitations in expression profiling methods.  
 
One useful approach to identify miRNA targets is based on the physical association 
between miRNA and targets. Biochemical purification of miRNA-RISC complex 
using antibodies against argonaute and GW182 proteins was used in several studies 
(Easow et al., 2007; Ender et al., 2008; Hendrickson et al., 2008; Karginov et al., 
2007b; Landthaler et al., 2008; Zhang et al., 2007). Our group previously reported a 
method based on Ago1 immunopurification (Ago1-IP) that proved to be effective 
(Easow et al., 2007). Eleven new targets were identified for miR-1, including some 
that had not been predicted. However, this protocol suffered from low sensitivity as 
less than 10% of the expected number of targets was enriched by IP (Easow et al., 
2007).  
 
In this part of my thesis, I present an improved Ago1 IP protocol which allowed 
identification of hundreds of potential miRNA targets and validation of a subset of 
these targets. By comparing the contextual features of targets identified by IP to the 
targets destabilized at the mRNA level upon Ago1 depletion, I showed that distinct 
contextual features are associated with the target groups identified by the two different 
biochemical approaches. The Ago1 IP-enriched set contains targets with shorter UTR 
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length, few sites and higher binding site accessibility. In contrast, the Ago1 RNAi-
upregulated set contains targets with longer UTR, multiple sites located in closer 
proximity but these sites are structurally less accessible. My work uncovered a 
previously unanticipated complexity of miRNA-target interactome in Drosophila. The 
computational analysis presented in this chapter was mainly accomplished by Dr 
Molly Hammell. Data analysed and discussed by Dr Stephen Cohen, Dr Molly 
Hammell and Hong Xin.  
 
3.2 Experimental assessment of an improved Ago1 immunopurification protocol 	  
In order to improve the sensitivity of miRNA IP with minimal loss of specificity, I 
tested a variety of antibody concentrations, incubation times and wash conditions 
(detailed description was shown in Fig 3.1). A serial dilution of anti-HA antibody 
(1:100, 1:200, 1:400, and 1:800) was used to identify the optimal working dilution. As 
shown by the immunoblot in Fig 3.2, Flag/HA-tagged Ago1 (F/H-Ago1, 
approximately 105 kilo delta) was consistently detected only in transgenic cells 
expressing F/H-Ago1, but not the control cells for all four concentrations of antibody 
dilutions. The detection signal gradually reduced as the concentrations of antibody 
used were decreased. α-tubulin protein was only detected in input but not on the IPed 
beads after washing, suggesting a relatively clean background in IP-enriched protein 
species after the wash steps.  
 
To assess the degree of sensitivity, I employed quantitative real time PCR to monitor 
miRNA levels using Taqman microRNA assay kit (Invitrogen). Four microRNAs were 
selected, representing a wide range of expression levels: miR-184 comprises 17% of 
S2 cell miRNA; miR-305: 1.5%; miR-7: 0.1%; miR-92b:  0.01% (Ruby et al., 2007). 
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Each of the 4 miRNAs was enriched >50 fold in IP from cells expressing F/H-Ago1 
protein compared to control cells not expressing the F/H-Ago1 transgene (Fig 3.3A, 
asterisks: p < 0.05). The control small nucleolus RNA (snoR227) showed no 
enrichment (log2 = 0.18). These data indicated that the IP protocol could effectively 
recover miRNAs over a broad range of expression levels without non-specific 
enrichment of other unrelated small RNAs. 
 
To assess the degree of mRNA target enrichment in the IP, I measured the recovery of 
reaper mRNA, a known target of miR-2a. mir-2a is abundantly expressed in 
Drosophila S2 cells ( The mir-2 family miRNAs compromises >13% of all S2 cell 
miRNAs). reaper mRNA was enriched ~32 fold by IP. A control mRNA (CG1969) 
lacking known miRNA binding sites, was not enriched (Fig3.3B). This suggested a 
substantial improvement as compared to 2-3 fold enrichment of reaper obtained 
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Figure 3. 1 The general workflow of an improved Ago1 immunopurification 
protocol.  
The protocol includes (1) Two times of pre-clearance step; (2) Overnight incubation 
with antibody; (3) Incubation with protein-G agarose beads pre-blocked with heparin 
for 4 hours; (4) Six to eight short washes (each no more than 10 minutes) with 200 
mM KCL at 4oC; (5) Protease K digestion and RNA extraction directly from the beads. 
Systematic testing using a combination of anti-Flag and anti-HA or anti-HA alone at 
various dilutions was performed to compare the efficacy of target RNA and protein 
recovery. We chose anti-HA at 1:200 dilution for subsequent IP-microarray profiling. 
Various combinations of wash buffers containing different salt concentrations ranging 
from 75 mM KCL to 200 mM KCL were tested. A salt concentration with 200 mM 
KCL showed efficient removal of non-specific binding, as judged by the difference in 
fold enrichment between reaper mRNA and the control, CG1969 (Fig 3.3B). The 
components in lysis and wash buffer were optimized with reference to target recovery 
(listed in Chapter 2 Materials and methods, Section 2.4. Immunopurification of 
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Figure 3. 2 A representative immunoblot of Ago1 IP on transgenic S2 cells 
expressing a Flag/HA epitope tagged Ago1 (+) or control S2 cells (-).  
Rat monoclonal anti-HA was used at different dilutions (Roche Cat No.:11867423001) 
for the IP. The same anti-HA antibody was used to detect Flag/HA-tagged Ago1 in 
immunoblots. Mouse monoclonal anti-tubulin was used as a control to monitor non-
specific binding of cellular proteins to the beads. 1% of input and 5% of the IP 
material was used for the blot. Antibody to α-tubulin was used to assess non-specific 
binding proteins in the beads.  
 
 
        
 
Figure 3. 3 miRNAs and validated known targets are enriched in Ago1 
immunopurified RNA complex 
(A) Enrichment of miRNAs measured by Q-PCR. Y-axis: fold enrichment (log2 
scale). Splicing RNA U27was used for normalization and snoR227 as a control. 
Results represent 3 independent IP experiments.  
(B) Enrichment of a known miR-2a target reaper by IP. Data normalized to rp49 for 3 
independent experiments (t-test, p<0.05). 
 
 
3.3 Expression profiling of mRNAs associated with Ago1 identified hundreds of 
IP-enriched transcripts 
 
I further examined the population of mRNAs that are specifically associated with 
Ago1 complexes by mRNA microarray profiling (carried out by the EMBL genecore 
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facility). Total RNA was recovered by IP with anti-HA from S2 cells expressing F/H- 
Ago1 and from control wildtype cells. After 2 rounds of linear amplification, the RNA 
was used to generate probes for expression profiling (Agilent Drosophila Array 2.0).  
Approximately 7000 transcripts can be detected reliably by expression profiling in S2 
cells and this number was used as the background total transcripts in IP-microarray 
data (Rehwinkel et al., 2006b). By microarray data analysis, I found that 1621 mRNAs 
were significantly IP enriched with a P value of <0.05. Of these, 1191 were enriched 
>1.4 fold, 464 were enriched >2 fold and 89 >4 fold (Fig 3.4A). Hence, a significant 
fraction of S2 cell transcripts were specifically associated with the Drosophila 
miRNA/Ago1 complex.  
 
As a control measurement, I first compared whether the IP method was enriched for 
transcripts that were expressed at higher levels. To do so, I firstly classified the 
mRNAs enriched in IP as targets with binding sites for the top 5 miRNA seed families 
(73% of all S2 cell miRNA sequencing reads); targets with sites for top 10 miRNA 
seed families (88% of all S2 cell miRNA sequencing reads) and targets for all S2 
miRNAs (a total of 26 distinct miRNA seed families in S2 cells). Fig 3.4B compared 
the distribution of abundance of all S2 mRNAs with that of IP-enriched transcripts 
with binding sites for S2 cell miRNAs. IP-enriched targets for all S2 miRNAs were 
slightly more abundant than S2 cell transcripts in general (p<1e-10; Fig 3.4B). IP-
enriched targets for the top 5 and top 10 seed families were also slightly more 
abundant (p=0.02; p=3.5e-6; Fig 3.4B). The differences in expression levels between 
IP-enriched mRNA versus total S2 cell transcripts were small in magnitude hence 
should not be a major concern for the usage of IP method. 
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I next assessed whether the enrichment by IP is dependent on the specific antibody 
being used. Similar IP experiments were carried out using monoclonal anti-Ago1 
(kindly provided by Dr. Mikiko Siomi). mRNA enrichment in the Ago1 IP was 
determined as compared to a control IP with monoclonal anti-Myc after normalization 
to rp49. Sixteen mRNAs were assayed by quantitative real time PCR (Q-PCR). All 
showed significant enrichment with a strong correlation between the two methods (Fig 
3.5, correlation coefficient r=0.71, p=0.0018). Therefore, the enrichment of target 





Figure 3. 4 Number of transcripts enriched in Ago1 IP and the mean abundance 
of transcripts.  
(A) Number of transcripts enriched by IP (p< 0.05) by expression profiling. X-axis: 
enrichment thresholds. (B) Transcript abundance distributions in arbitrary units. Box 
and whisker plots, show the 1st quartile and 3rd quartile (boxes) and the range of non-
outliers (whiskers). IP-enriched transcripts show a slight bias towards higher 
abundance, compared to all S2 RNAs (median 351 vs 210; p<1e-10 Wilcoxon test). 
The difference was smaller for the IP-enriched set with sites for abundant miRNAs 
(248 vs 210; top 5 seed, p=0.02). 
 
 






Figure 3. 5 Validation of selected IP-enriched genes by independent IP-Q-PCR.  
S2 cell lysates were immunoprecipitated with anti-Ago1 or with anti-Myc as a control. 
The level of selected mRNAs was assayed in the two samples by quantitative real time 
PCR and the fold enrichment in the Ago1 IP determined relative to the anti-Myc 
sample after normalization to rp49. RNAs from three independent IP experiments were 
quantified by Q-PCR in triplicates. The distribution of fold enrichment determined by 
Q-PCR for the 16 selected genes (X-axis, right panel) was compared to fold 
enrichment obtained from microarray analysis (Y-axis, both in log2 scales) and the 
correlation coefficient and associated p value was calculated and shown in the plot.   
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Table 3. 1 List of microRNA seed families expressed in Drosoiphila S2 cells. 
miRNAs were clustered into families based on shared seed sequences and ranked by 
abundance of sequencing reads in the data set of (Ruby et al., 2007).  miRNAs with 
<0.05% of sequence reads, or <10 reads were not included in the set of all miRNAs.  
 
3.4 Experimental validation of target enrichment in Ago1 IP 
 
With the help by Molly Hammell, I examined the performance of Ago1 IP with 
reference to a set of experimentally validated miRNA-target pairs: a non-redundant set 
of 67 validated positives and 29 validated negatives (Table 3.2). Please be noted that a 
validated true target was only considered once even if it has sites for more than one 
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miRNAs. We found significant enrichment for validated true targets in the IP-enriched 
set than expected after normalization for the number of total transcripts in each 
category (Fig 3.6). Enrichment was 3.3 fold for targets of the 5 and 10 most abundant 
miRNA seed families (20 positives / 489 IP-enriched with sites for the top 10 
miRNAs; p=6.0e-5). The enrichment was slightly reduced but remained significant 
when all S2 cell miRNAs were considered (23 positives / 745 IP-enriched, p=3.6e-4). 
Importantly, we didn’t find enrichment for the 29 miRNA-target pairs that tested 
negative experimentally, suggesting the IP protocol I used could distinguish validated 
true targets from those false positives. It should be noted that some validated targets 
were not enriched by IP. This could be explained by the possibility that some of the 
validated pairs might not be functional in S2 cells.  
 
It is still formally possibly that the enrichment of mRNAs in the Ago1 IP was due to 
Ago1 protein complex independent of the presence of miRNAs. To address this 
question, I used antisense oligonucleotides to deplete miRNAs in S2 cells (Horwich 
and Zamore, 2008a). miR-184 was chosen because many of its predicted targets were 
enriched by IP (n=32; Table 3.3). Cells were treated with anti-miR-184 or with a 
scrambled sequence control and subjected to IP with anti-Ago1. 9 of the 32 miR-184 
targets were assayed by Q-PCR. IP recovery of 7 out of 9 was significantly lower in 
miR-184 depleted cells (Fig 3.7), arguing that majority of IP-enriched mir-184 targets 
were sensitive to the change in mir-184 levels. The partial reduction in recovery likely 
reflects incomplete depletion of miR-184. Another possibility is that 8 out of 9 
selected targets have binding sites for other miRNAs besides mir-184, including sites 
for 4 of the top 10 seed families. Hence, this experiment clearly demonstrated the 
enrichment of mRNAs in my Ago1 IP set was dependent on the presence of miRNAs. 
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Figure 3. 6 Comparison of IP results with experimentally validated miRNA 
targets. 
Fold enrichment of the non-redundant target set for the 5 and 10 most abundant S2 
miRNA seed families and for all S2-expressing miRNA seed families (set data in 
Table S3). Y-axis: enrichment calculated as the number of validated targets present in 
IP-enriched transcripts divided by the number of validated in IP non-enriched 
transcripts after normalization for the total number of transcripts in each category. The 
set contains a total of 67 validated positive and 29 validated negative targets for all S2 
miRNA seed families respectively (list for miRNA seed families, Table S2). P values 
are calculated using Fisher’s Exact Two-tailed Test.  
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Figure 3. 7 Effect of miR-184 depletion on the recovery of predicted mir-184 
targets by IP. 
miRNP immunopurification is performed on mir-184-depleted S2 cells or control cells 
treated with sequence scrambled control oligonucleotides. Y-axis: Relative IP 
enrichment was calculated by normalizing IP fold enrichment in miR-184 depleted 
cells ( grey bars) to IP fold enrichment in control cells (black bars). The relative 
transcripts level (normalized to rp49) recovered by Ago1 IP were quantified by Q-PCR 
and compared to a control IP with empty protein-G agarose beads. Nine IP-enriched 
mir-184 targets are selected for Q-PCR quantification. The control gene, reaper, is a 
validated mir-2a target but lacking predicted miR-184 sites. Asterisks: p<0.05 
(student’s T test) 
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Table 3. 2 The non-redundant set of validated miRNA target pairs. 
A non-redundant set of experimentally tested miRNA target pairs was selected using 
the following criteria: (1) Transcript and microRNA are both expressed endogenously 
in Drosophila S2 cells. (2) Transcripts that tested positive for more than one miRNA 
were only counted once. (3) Transcripts that tested positive for any miRNA were 
considered testable, even if they were negative for the S2 cell expressed RNAs. These 
were scored as validated negative. Target validation is reported in the papers listed in 
miRNA Seed Family miR Expression Group Gene Name CG Identifier
identified  by 







bantam bantam Top 5 W CG5123 ip 1 Brennecke et al, 2003  Cell 113: 25
bantam bantam Top 5 Mad CG12399 kd 1 Robins et al, 2005 PNAS 102: 4006
bantam bantam Top 5 - CG5919 - 0 Stark et al., 2005.  Cell 123: 1133
bantam bantam Top 5 S CG4385 kd 1 Stark et al., 2005.  Cell 123: 1133
mir_13a miR-2a Top 5 spas CG5977 - 0 Rehwinkel, et el., 2006. MCB 26: 2965
mir_13a miR-2a Top 5 Tab2 CG7417 - 0 Rehwinkel, et el., 2006. MCB 26: 2965
mir_13a miR-2a Top 5 Reg-5 CG2928 ip 0 Rehwinkel, et el., 2006. MCB 26: 2965
mir_13a miR-2a Top 5 Exn CG3799 - 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_14 mir_14 Top 5 hkl CG10473 - 0 this work
mir_14 mir_14 Top 5 InR CG18402 kd 0 this work
mir_14 mir_14 Top 5 - CG18604 - 0 Rehwinkel, et el., 2006. MCB 26: 2965
mir_14 mir_14 Top 5 Eip75B CG8127 - 0 Stark et al., 2005.  Cell 123: 1133
mir_14 mir_14 Top 5 dpld CG1624 ip 0 Stark et al., 2005.  Cell 123: 1133
mir_14 mir_14 Top 5 EcR CG1765 - 1 Stark et al., 2005.  Cell 123: 1133
mir_14 mir_14 Top 5 par-6 CG5884 - 0 Stark et al., 2005.  Cell 123: 1133
mir_184 mir_184 Top 5 cora CG11949 - 0 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 nrv2 CG9261 - 0 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 Gli CG3903 - 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 ttk CG1856 - 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 Nrx-IV CG6827 - 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 rn CG32466 - 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 chp CG1744 ip 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 santa-maria CG12789 ip 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 Lac CG12369 ip/kd 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 sinu CG10624 ip/kd 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 pck CG14779 ip/kd 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 - CG6583 ip/kd 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 - CG1298 ip/kd 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_184 mir_184 Top 5 Cont CG1084 ip/kd 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_2a mir_2a Top 5 drpr CG2086 - 0 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_2a mir_2a Top 5 Ice CG7788 ip/kd 0 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_2a mir_2a Top 5 pnr CG3978 - 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_2a mir_2a Top 5 hep CG4353 - 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_2a mir_2a Top 5 crq CG4280 ip 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_2a mir_2a Top 5 scyl CG7590 ip 1 Kertesz et al., 2007.  Nat Genet 39: 1278
mir_2a mir_2a Top 5 malpha CG8337 - 1 Lai et al, 2005 Genes Dev 19: 1067
mir_2a mir_2a Top 5 rpr CG4319 ip/kd 1 Stark et al, 2003 PLoS Biol 1: E60
mir_2b mir_2a Top 5 Sema-1b CG6446 kd 0 Rehwinkel, et el., 2006. MCB 26: 2965
mir_2b mir_2a Top 5 - CG4851 ip 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_2b mir_2a Top 5 - CG31886 kd 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_2b mir_2a Top 5 - CG1969 - 0 Stark et al., 2005.  Cell 123: 1133
mir_2b mir_2a Top 5 - CG7956 ip 0 Stark et al., 2005.  Cell 123: 1133
mir_2b mir_2a Top 5 - CG4269 ip 1 Stark et al., 2005.  Cell 123: 1133
mir_2b mir_2a Top 5 GLaz CG4604 kd 1 Stark et al., 2005.  Cell 123: 1133
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 exu CG8994 - 0 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 fu12 CG17608 - 0 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG32103 CG32103 - 0 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 spz CG6134 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 Klp68D CG7293 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 D19A CG10269 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG31689 CG31689 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 pes CG7228 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG8451 CG8451 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG10631 CG10631 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG7995 CG7995 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG6745 CG6745 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG16708 CG16708 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 RhoGAP92B CG4755 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG33144 CG33144 - 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 Rab9 CG9994 ip 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG11967 CG11967 ip 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 cbt CG4427 ip 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG3566 CG3566 ip/kd 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG12024 CG12024 ip/kd 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 step CG11628 ip/kd 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 Eip63E CG10579 kd 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG9523 CG9523 kd 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG8298 CG8298 kd 1 this work
mir_309 cluster mir_2a, mir_3, mir_4, miR_5, mir_279 Top 5 CG16718 CG16718 kd 1 this work
mir_276b miR_276a Top 10 kel CG7210 - 0 Robins et al, 2005 PNAS 102: 4006
mir_34 miR-34 Top 10 Eip74EF CG32180 - 1 Burgler et al, 2005 BMC Genomics 6: 88
mir_34 miR-34 Top 10 Su(z)12 CG8013 - 1 Robins et al, 2005 PNAS 102: 4006
mir_12 miR-12 All S2 - CG10011 - 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_317 miR-317 All S2 yellow-c CG4182 - 0 Robins et al, 2005 PNAS 102: 4006
mir_7 miR-7 All S2 HLHm3 CG8346 - 1 Lai et al, 2005 Genes Dev 19: 1067
mir_7 miR-7 All S2 aop CG3166 kd 1 Li et al, 2005 Cell 123: 1267
mir_7 miR-7 All S2 h CG6494 ip/kd 1 Stark et al, 2003 PLoS Biol 1: E60
mir_8 miR-8 All S2 sd CG8544 - 0 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 - CG4484 - 0 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 pygo CG11518 - 0 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 Nedd4 CG7555 - 0 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 - CG18622 ip 0 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 Gug CG6964 - 1 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 disp CG2019 - 1 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 orb2 CG5735 - 1 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 wls CG6210 - 1 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 Mip CG6456 - 1 Stark et al., 2005.  Cell 123: 1133
mir_8 miR-8 All S2 - CG1882 ip 1 Stark et al., 2005.  Cell 123: 1133
mir_9a miR-9a All S2 brat CG10719 - 0 Rehwinkel, et el., 2006. MCB 26: 2965
mir_9a miR-9a All S2 - CG1172 - 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_9a miR-9a All S2 - CG31712 - 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_9a miR-9a All S2 - CG33087 - 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_9a miR-9a All S2 Arc1 CG12505 ip/kd 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_9a miR-9a All S2 betaTub60D CG3401 kd 1 Rehwinkel, et el., 2006. MCB 26: 2965
mir_9b miR-9a All S2 htt CG9995 - 0 Rehwinkel, et el., 2006. MCB 26: 2965
mir_9b miR-9a All S2 Vha68-1 CG12403 kd 1 Rehwinkel, et el., 2006. MCB 26: 2965
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the table. “1” means tested positive and "0” means tested negative. For those labeled 
“this work” 3’ UTRs were cloned into a firefly luciferase reporter and tested for 
regulation by coexpression with the miRNA in S2 cells. 
 
3.5 Experimental validation of selected mir-184 targets identified by Ago1 IP 
 
From the set of computationally predicted miR-184 targets, I selected 17 that were IP 
enriched and 17 that were not, for comparison. Transcript levels were measured by Q-
PCR following miR-184 depletion. 12/17 predicted targets were upregulated in cells 
depleted of miR-184 (p<0.05; Fig 3.8; genes selected from the list in Table 3.3). 
Importantly, two control mRNAs, reaper and act42A, did not change the expression 
level. Strikingly, as a comparison,, I also quantified another 17 genes that were not 
enriched by IP and found only 2 of them were upregulated in miR-184 depleted cells 
(Fig 3.8). Therefore, the IP-enriched mRNA targets appeared to be a good prediction 
for real targets, whose mRNA levels were sensitive to miRNA activity.  
 
To further assess the functionality of targets enriched in IP, Luciferase reporter assays 
were employed. 5 of the 12 targets upregulated on miR-184 depletion have been 
validated previously (Kertesz et al., 2007b). I tested one of these as a positive control, 
5 other novel upregulated transcripts and 3 from the IP, but not upregulated set (Table 
3.4). Control UTRs lacking mir-184 sites were unaffected by miR-184 depletion. The 
6 upregulated transcripts showed modest but significant increases in luciferase activity 
upon miR-184 depletion, but the other 3 IP positive transcripts did not (Fig 3.9; 
asterisks p<0.05).  
 
Table 3.4 summarizes experimental tests used to validate the predicted miR-184 
targets as recovered by IP. 12 of the selected 17 targets were upregulated at the RNA 
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level in miR-184 depleted cells. while 5 of them were not regulated at the RNA level. 
All 6 tested to be positive in luciferase assay were also upregulated in mRNA level 
upon mir-184 depletion; this contrasted with the 3 tested negative in luciferase assay, 
which were also not upregulated in miR-184 depleted cells. This suggested for IP-
enriched mir-184 targets, mRNA level change correlated well with site functionality. 
What is the reason then for the 3 false positive sites for mir-184 to be enriched? One 
possibility is that these 3 targets were enriched by IP due to other miRNAs (all contain 
at least one site for other S2 miRNAs). Nevertheless, our experiment suggested the set 
of IP-enriched transcripts and upregulated upon miRNA depletion should be 






Figure 3. 8 Effect of miR-184 depletion on the expression level of mir-184 targets 
for IP-enriched Vs non IP-enriched sets.  
From the set of computationally predicted miR-184 targets, I selected 17 that were 
enriched by Ago1 IP and 17 that were not IP enriched. Transcript levels were 
measured by Q-PCR following miR-184 depletion and compared to cells treated with a 
control antisense oligonucleotide after normalization to rp49. Y-axis: Expression fold 
change in log 2 scale.  Two control genes, reaper and act42A, both lacking predicted 
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mir-184 sites, were included. Data represent at least three independent mir-184 




Figure 3. 9 Luciferase assay validation on selected IP-enriched mir-184 targets. 
Y-axis: fold de-repression is calculated as: Relative firefly luciferase activity in mir-
184 depleted cells compared to cells treated with control oligos after normalization to 
renilla luciferase control. Control reporters, are a UTR reporter with the 3’ UTR of 
reaper (a mir-2a target), and a reporter with the SV40 UTR. Both are lacking miR-184 
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Table 3. 3 Predicted miR-184 targets enriched in Ago1 IP. 
Transcripts IP-enriched by > 1.4 fold (log2 > 0.5) were considered. The lists show 
genes containing at least one predicted mir-184 binding site. Target predictions were 
as in: (Kheradpour et al., 2007); (Hammell et al., 2008a). Targets that were commonly 
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Table 3. 4 Summary of IP target validation. 
Seventeen IP-enriched mir-184 targets as shown in Table 3.3 are selected for further 
validation by three different means. 1) IP recovery of nine (out of the seventeen) was 
assessed in cells treated with either anti-mir-184 antisense oligo or random control 
sequences. Seven out of the nine was found to have lower enrichment in miR-184 
depleted cells (Fig 3.7), indicating that binding to miR-184 contributes to IP 
enrichment of these genes; 2) All seventeen target mRNAs were measured in mir-184 
depleted S2 cells and it turned out twelve of them showed significant upregulation (Fig 
3.8). Nine out of the twelve genes, whose mRNA level upregulated upon mir-184 
depletion, is selected for 3’UTR luciferase assay. For comparison, another three out of 
the five genes, whose mRNA didn’t upregulate upon mir-184 depletion are also 
selected for luciferase assay (Fig 3.9). “+” Indicated positive results, while “-“ 
indicated negative results. K, indicates the same UTR was validated by an independent 
study (Kertesz et al., 2007a)    
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3.6 Seed type enrichment of the target sites in Ago1 IP-enriched transcripts 
 
The pairing of residues 2-8 of the miRNA 5’end to mRNA 3’UTR, the “seed”, plays a 
critical role in target repression (Baek et al., 2008; Brennecke et al., 2005a; Doench 
and Sharp, 2004b; Krek et al., 2005; Lewis et al., 2005; Lim et al., 2005; Selbach et 
al., 2008; Stark et al., 2005). However, there are also experimental evidence suggesting 
stringent seed match is not required and “G:U” match could be tolerated in certain 
miRNA-target pairs (Brennecke et al., 2005a; Johnson et al., 2005; Nahvi et al., 2009; 
Simon et al., 2008; Varghese and Cohen, 2007a; Vella et al., 2004).  
 
The frequency of occurrence of particular seed types was calculated: including 8mer 
seed matches, which are sufficient to confer robust regulation; 7mer seed matches, 
which confer weak regulation unless supplemented by additional pairing as well as 
6mer matches that require extensive base pairing at miRNA 3’end (Brennecke et al., 
2005a). The possible enrichment of G:U base pairing was also assessed. By 
computational analysis for the top 5 miRNA seed families (73% of all miRNA reads), 
I observed statistically significant enrichment for 8mer and 7mer matches beginning in 
positions 1 or 2; and 6mer matches beginning in position 2 (Fig 3.10; asterisks 
p<0.05). Four of these were enriched for top 10 seed families (88% of miRNAs) and 3 
were enriched when the analysis was extended to all S2 cell miRNAs. There was no 
enrichment for seeds with G:U pairing or mismatches. This result suggested that the 
presence of perfect 8mer, 7mer and 6mer seed matches improved the chance to be 
recovered by IP. The degree of enrichment decreased, as more miRNAs were included 
for analysis. This might be due to the fact that many miRNAs were expressed at 
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relatively low levels, which contributed less to enrichment, but increased the total 





Figure 3. 10 miRNA target seed type enrichment analysis in Ago1 IP-enriched 
transcripts.  
“8mer, 7mer or 6mer” indicates the length of the seed match. “Position” indicates the 
first paired position from the miRNA 5’ end. Y-axis: fold enrichment calculated as % 
sites of each type in IP-enriched transcripts divided by % of matching sites in IP non-
enriched transcripts. P values: Fisher’s Exact Test (asterisks indicates p<0.05). 
 
3.7 Other contextual features enriched in Ago1 IP-enriched transcripts 
 
The hybrid energy of base pairing between miRNA and target is considered to be an 
important factor for stable miRNA-target binding. One would assume that a stable 
binding between miRNA and target should be helpful for IP recovery. By comparing 
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the free energy of miRNA-target base pairing for transcripts enriched by IP with those 
not enriched (Table 3.5; ΔGhybrid calculated as in Hammell et al., 2008a), Dr Hammell 
and I found the distribution of binding energies was significantly shifted towards more 
stable duplexes in IP-enriched transcripts (p=0.005 using a two-sample Kolmogorov-
Smirnov test as shown in Table 3.5). The correlation between binding energy ΔGhybrid 
and degree of enrichment in the IP set was modest (r= -0.60, r is negative because the 
value (kal/mol) for MFE is negative). The statistical significance was on the borderline 
(p=0.0503, Table 3.5). This indicated that IP does not strongly select for higher 
binding energy. 
 
Previous studies have developed ways to predict site ‘openness’ and suggested that 
this could improve computational target prediction (Hammell et al., 2008a; Kertesz et 
al., 2007b; Long et al., 2007). The “openness” is a measurement of local secondary 
structure in the UTR. Intuitively, one might expect that the miRNA-binding site should 
be in principle “open” in order for easy loading of miRNA-RISC complex. By 
computational analysis as described in (Hammell et al., 2008a), I found a significant 
shift toward higher site openness in IP-enriched targets compared to those not enriched 
(KS 2-sample, p=4e-06; Table 3.6). The degree of enrichment correlated well with 
increasing site openness (r =0.865, p=0.006; Table 3.6). A comparable correlation was 
found when all S2 mRNAs were used as the control set (r =0.868, p=0.005; Table 3.7). 
 
It was shown that the “openness” of neighboring sequences nearby the miRNA 
binding sites, typically of length from 50 to few hundreds of nucleotides, played an 
important role in target recognition (Hammell et al., 2008a; Kertesz et al., 2007a). A 
previous analysis using a different miRNP protein in C elegans (AIN-IP, GW182) 
found that a 25 nucleotides upstream window had the best correlation with IP 
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enrichment, but did not find evidence for downstream openness (Hammell et al., 
2008a).To examine the impact of neighboring sequences on site recognition in 
Drosophila S2 cells, a window size from 5 to 95 nucleotides in length upstream and 
downstream of the site was systematically evaluated for structural openness, as shown 
in Table 3.8. To better visualize the data shown in Table 3.7 and Table 3.8, a surface 
plot was presented in Fig 3.11 to demonstrate the correlation coefficient between 
degree of openness and enrichment in the IP set, compared to all S2 transcripts. 
Upstream of the site, the correlations were significant for sequence windows of up to 
50 nucleotides. Comparatively, the downstream openness was more extensive: the 
correlations were significant for windows from 10-70 nucleotides with an optimum at 
50 nucleotides (Table 3.8, Fig 3.11). Hence, the IP-enriched transcripts were 
structurally open at the miRNA binding sites as well as the upstream and downstream 
flanking sequences. The differences in IP-enrichment for downstream openness 
between Drosophila Ago1 IP and C elegans AIN-IP might be due the species-specific 
differences in UTR composition during evolutionary selection. The differences in 
antibodies used (Our IP used antibody against Drosophila Ago1 and the other group 
used antibody against GW182 in C elegans) might also result in some differences in 
RISC complex being sampled.   
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Table 3. 5 Analysis of enrichment for stable hybridization binding energy, MFE, 
ΔGhybrid. 
The table calculated the % of miRNA binding sites in Ago1 IP-enriched transcripts 
falling in each ΔGhybrid bin (kcal/mol) and fold enrichment was calculated as: % of 
miRNA binding sites in Ago1 IP-enriched group divided by % of miRNA binding sites 
in non-IP enriched group. Binding sites for all detectable S2 miRs were used for this 
analysis. Two types of P-values were used to assess the significance of these 
enrichments. The Kolomogorov-Smirnov test (KS) P-vaues are given as well as 
Pearson correlation coefficients and associated P-values, which were calculated for all 





Table 3. 6 Analysis of enrichment for miRNA binding site openness for IP-
enriched trascripts using non-IP enriched transcripts 
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The table shows a comparison of Ago1 IP-enriched transcripts to control Non-IP-
enriched transcripts. Binding sites for all detectable S2 miRs were used for this 
analysis. Two types of P-values were used to assess the significance of these 
enrichments: 1) The Kolomogorov-Smirnov test (KS) P-values; 2) Pearson correlation 





Table 3. 7 Analysis of enrichment for miRNA binding site openness for IP-
enriched transcripts using all S2 cells transcripts as controls 
The table shows a comparison of Ago1 IP-enriched transcripts to all S2 cell transcripts 
as controls. Analysis methodology is same as described in Table 3.4 
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Table 3. 8  Analysis of miRNA binding site openness and flanking region 
openness in Ago1 IP-enriched group.   
Drosophila melanogaster 3' UTRs were folded using the Vienna RNAfold package. 
The average percent open nucleotides were calculated within varying local sequence 
windows from 5 to 95 nucleotides (nt) around each miRNA binding site.  Fold 
Enrichments were calculated to assess the correlation between accessibility of local 
sequence windows and enrichment in the list of Ago1 IP-enriched transcripts versus all 
detectable S2 cell transcripts. For each local sequence window (upstream or 
downstream of the binding site, or along the binding site itself), this table lists the 
Pearson correlation coefficient and associated P-value. The most optimal windows are 
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Figure 3. 11 Graphic representation of miRNA binding site openness and 
flanking region openness as shown in Table 3.8.  
Surface plot showing Pearson correlation coefficient (Y-axis) versus sequence window 
size upstream and downstream of miRNA sites (X-axis, nt). The correlation coefficient 
measures the correlation between IP enrichment and degree of local nucleotide 
openness, binned from 10% to 80%. IP fold enrichment is calculated as % of all 
miRNA sites in IP-enriched transcripts divided by % of all miRNA sites in all S2 cell 
transcripts for each bin (Hammell et al., 2008a). The red triangle indicates the 
correlation coefficient for openness of the miRNA site (arbitrarily placed at 50nt on 
the X-axis); Upstream = sequences 5’ of the site, downstream = sequences 3’ of the 
site. Enrichment and correlation coefficients were calculated for windows from 5 to 
95nt (Table 3.6-3.8). 
 
3.8. Comparison of targets identified by Ago1 IP and Ago1 depletion 
 
mRNAs upregulated upon Ago depletion were shown to be enriched with miRNA 
target sites (Baek et al., 2008; Eulalio et al., 2007b; Karres et al., 2007; Rehwinkel et 
al., 2006b). It would be rather interesting to compare the targets enrichment in the 
Ago1 IP-enriched set versus the Ago1 RNAi-upregulated set in Drosophila S2 cells. 
Strikingly, there was less than one third overlap in the RNAs identified by the two 
methods, though both methods were shown to have enrichment for miRNA binding 
sites (Fig 3.12). A similarly low degree of overlapping was also shown in Ago2 IP of 
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miRNA targets in mammalian cells versus targets down-regulated upon miRNA 
overexpression (Hendrickson et al., 2008; Karginov et al., 2007b). Therefore it would 
be interesting to compare what kind of targets was enriched in these two sets. 
 
I didn’t find significant differences in seed type enrichment between the two sets: both 
groups were enriched for perfect 8mers, 7mers, and 6mers, but there were some 
differences in starting positions of seed pairing between Ago1 IP-enriched group as 
compared to Ago1 RNAi-upregulated group (Fig 3.13). There was an interesting 
under-representation for stronger binding energy in the upregulated transcript set as 
compared to total (p = 0.01, cumulative distribution plot in Fig 3.14). Consistently, a 
significant anti-correlation between more stable hybrids and degree of enrichment in 
the upregulated transcript set was observed (r=0.82, p=0.004, Table 3.9). These results 
suggested unlike Ago1 IP-enriched set, which marginally select for stronger binding 
energy, Ago1 RNAi-upregulated transcripts contained energetically weaker binding 
sites (r=-0.60, p=0.0503, Table 3.5, Fig 3.14). 
 
I next checked what kind of UTR types were enriched in Ago1 IP. One might expect 
IP should be enriched for longer UTRs since they would contain more miRNA binding 
sites. Instead, I found RNAs with shorter UTRs were enriched in the IP set (Fig 
3.15A). There were fewer sites in IP enriched UTRs without change in site density 
(p=0.1; Fig 3.15B). As a sharp comparison, Ago1 RNAi upregulated set was enriched 
for longer UTRs (Fig 3.15A). Site density was also higher in UTRs of the upregulated 
set compared to the IP set ( Fig 3.15B; p = 0.01) or all transcripts (p=4.5e-7). It is 
intriguing that IP was selecting for shorter UTRs, perhaps these transcripts were 
relatively more stable to sustain the wash steps. The reason for enrichment of longer 
UTRs with higher site density in the Ago1 RNAi upregulated set might be because the 
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sites located close together could act synergistically to promote target destabilization 
(Baek et al., 2008; Grimson et al., 2007b; Selbach et al., 2008). 
 
There were significant differences between the IP and upregulated sets in the degree of 
openness of target sites and flanking sequences. Firstly, there was no enrichment for 
site openness in the Ago1 RNAi-upregulated set (r=0.2, p=0.62; Table 3.10). 
Interestingly, the enrichment for upstream and downstream openness was also 
substantially distinct between the two sets. Fig 3.16 is a surface plot presentation 
showing the correlation coefficients for upstream and downstream openness and the 
binding site itself for the Ago1 RNAi-upregulated group at various window sizes. The 
correlations for upstream site openness were only significant for windows up to 35 
nucleotides, while the correlation for downstream openness was relatively poor (Table 
3.11; compare with Fig 3.7). Fig 3.17 compared the enrichments for upstream and 
downstream openness at optimal sequence windows between the two sets. There was a 
clear difference in enrichment for downstream openness (enrichment curve shown in 
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Figure 3. 12 A comparative analysis on Ago1 IP-enriched transcripts Vs Ago1 
RNAi-upregulated transcripts. 
Numbers of transcripts with miRNA sites identified by IP-microarray or by Ago1 
RNAi-microarray assay (Eulalio et al., 2007a). IP-enriched used a cutoff > 1.4 fold 
(log2 > 0.5) with a P-value < 0.05. Ago1 RNAi-microarray identified 451 transcripts 
upregulated by >1.5 fold (P < 0.05, Eulalio et al., 2007b). Numbers of four categories 
of transcripts are shown: transcripts containing sites for top 5, top 10, or all S2 miRNA 
seed families and all S2 transcripts with or without predicted miRNA sites. Numbers 
for overlapping transcripts in each category are indicated.  
 
 
	   71	  
 
Figure 3. 13 Comparison of seed type enrichment of targets identified by Ago1 IP 
and Ago1 depletion. 
The occurrence of miRNA seed matches was examined for 451 transcripts upregulated 
upon Ago1 depletion (array data extracted from Eulalio et al., 2007b). The analysis 
considers sites for all 26 S2 miRNA seed families. For this analyses we used the full 
set of 7000 S2 cell transcripts as the control group for both the IP enriched and 
upregulated transcript sets.  The magnitude of the differences between each group and 
this control will be less than between each group and the set of unaffected transcripts, 
because the affected transcripts are also included in the control set (compare the IP set 
with Fig 3.6). Use of a common control set allows comparison between the two 
experiments.  
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Figure 3. 14 Comparison of binding site energy of targets identified by Ago1 IP 
and Ago1 depletion.  
The minimum free energy (X-axis, also called ΔGhybrid, kcal/mol) of miRNA-target 
duplex was calculated as in (Hammell et al., 2008b) and plotted as cumulative 
distribution function for all S2 miRNA families. The Kolmogorov-Smirnov test shows 
that IP-enriched group (curve in blue) shifted towards slightly more stable binding 
(kcal/mol, X-axis; p = 0.01) while the overall distribution of transcripts in Ago1 RNAi 
group shows depletion for stable binding (curve in magenta, p = 0.01). The binding 
energy distribution for all S2 transcripts with miR sites were shown in grey and used 
as the control. Y-axis: percentages of total transcripts in each category.   
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Table 3. 9 Analysis of enrichment for stable hybridization binding energy (MFE) 
in Ago1 RNAi-upregulated group.                                                                                           
The table calculated the % of miRNA binding sites in Ago1 RNAi-upregulated 
transcripts falling in each ΔGhybrid bin (kcal/mol) and fold enrichment was calculated 
as:  % of miRNA binding sites in Ago1 RNAi-upregulated group divided by % of 
miRNA binding sites in all detectable S2 cell transcripts. Binding sites for all 
detectable S2 miRs were used for this analysis. A cumulative sum of each category 
was also shown and the cumulative distribution curve was shown in Fig 3.14. Two 
types of P-values were used to assess the significance of these enrichments. The 
Kolomogorov-Smirnov test (KS) P-vaues are given as well as Pearson correlation 
coefficients and associated P-values, which were calculated for all bins with > 10 
objects (no tails).   
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Figure 3. 15  Differences in UTR length and miRNA site density distributions 
between Ago1 IP-enriched group and Ago1 RNAi-upregulated group. 
(A) UTR length distribution among different transcript groups. Y-axis: median UTR 
length (nt) represented by grey squares. The range between 1st and 3rd quartiles are 
indicated by bars. P values: Wilcoxon U Test, Bonferroni Corrected (4 tests/group). 
The median for the Ago1 RNAi set is 262 nt longer than the IP set (p=6e-21) and 187 
nt longer than for all RNAs with sites (p=6e-13). The IP set was 75nt shorter than all 
RNAs with sites (p=5e-7). 
(B) Site density profiles in IP-enriched vs Ago1 RNAi-upregulated targets and all S2 
miRNAs. The upregulated set has more sites/transcript than the IP set (median shift 4, 
p=2e-18) or than all RNAs with sites (median shift 3, p=1e-14). Median site density 
was 6.9/500nt in the upregulated set vs 6.0 for the IP set and 5.6 for all RNAs. These 
differences were significant using a KS 2-sample test. 
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Figure 3. 16 Assessment of miRNA site openness, upstream openness and 
downstream openness for the Ago1 RNAi upregulated set vs all S2 RNAs 
with sites.  
Surface plot showing Pearson correlation coefficient (Y-axis) versus sequence window 
size upstream and downstream of miRNA sites (X-axis, nt). See Fig 3.11 for detailed 
description. Compared with Fig 3.11, there is much limited structural accessibility 
across downstream (blue surface plot) and upstream windows (green surface plot) 
flanking the binding sites from 5nt to 95nt in window length, as well as the miRNA 
binding sites themselves (red triangle). This suggested distinctive differences in 
structural accessibility between IP-enriched miRNA targets and Ago1 RNAi-






	   76	  
 
Table 3. 10 Analysis of enrichment for miRNA binding site openness for Ago1 
RNAi-upregulated transcripts as compared to all detectable S2 cell 
transcripts 
The table shows a comparison of Ago1 RNAi-upregulated transcripts to control (all 
detectable S2 cell transcripts). Binding sites for all detectable S2 miRs were used for 
this analysis. Two types of P-values were used to assess the significance of these 
enrichments: 1) The Kolomogorov-Smirnov test and its P-values; 2) Pearson 
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Figure 3. 17 Fold enrichment for the optimal upstream windows (35nt) and 
downstream windows (50nt) in IP-enriched and Ago1 RNAi upregulated 
sets.  
X-axis: average nucleotide openness binned from 10% to 80%. Y-axis: fold 
enrichment is calculated as % of all miRNA sites in either IP-enriched group or Ago1 
RNAi-upregulated group divided by % of all miRNA sites in all S2 cell transcripts for 
each bin (Hammell et al., 2008a). The list of all S2 transcripts with sites was used as 
the common control. Pearson’s correlation coefficient, r and associated p values are 
shown. 
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Table 3. 11 Analysis of miRNA binding site openness and flanking region 
openness in Ago1 RNAi upregulated group.   
Fold Enrichments were calculated to assess the correlation between accessibility of 
local sequence windows and enrichment in the list of Ago1 RNAi-upregulated group 
versus all detectable S2 cell transcripts.  For each local sequence window (upstream or 
downstream of the binding site, or along the binding site itself), this table lists the 
Pearson correlation coefficient and associated P-value. The most optimal windows are 
listed in red for statistically significant correlations. More detailed describtion could be 
found in Table 3.6. 
 
3.9 Functional clustering suggests distinct biological functions in the two target 
groups 
 
To explore what types of functions these groups of transcripts encode, I analyzed Gene 
Ontology annotations using David 78 bioinformatics tools 
(http://david.abcc.ncifcrf.gov/). Functional annotation clustering results for the 745 
transcripts enriched in Ago1 IP, the 394 upregulated by Ago1 RNAi and the 121 
enriched in both groups are shown in Table 3.12 (only transcripts with at least one 
predicted S2 miRNA site were included for analysis). Interestingly, the IP-enriched 
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transcripts were over-represented for functions related to lipid, glucose and amino acid 
metabolism, mitochondrial function, and other enzymatic activities. The top clusters in 
the Ago1 RNAi upregulated group involved signal transduction, cell differentiation, 
morphogenesis and other developmental processes. Since the S2 cells are considered 
to be macrophage-like cells in Drosophila, it is conceivable that the targets 
downregulated upon Ago1 depletion might be involving in functions that are not 
favorable for this cell type; on the contrary, the IP-enriched set might be the genes 
fine-tuned by miRNAs involving basic cellular homeostasis and functions  that has 
been overlooked previously (Stark et al., 2005). The latter type of miRNA regulatory 





Table 3. 12 Gene ontology analysis of Ago1 IP-enriched transcripts and 
transcripts upregulated by Ago1 RNAi. 
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David bioinformatics tools (http://david.abcc.ncifcrf.gov/) were used for gene ontology 
analysis for IP-enriched (745 transcripts with 810 DAVID IDs) and Ago1 RNAi-
upregulated transcripts (394 transcripts with 450 DAVID IDs) for all S2 miRNAs. The 
total S2 transcripts (top 7k) were used as the background list. The enrichment score 
(EASE) and P values were generated for each set of analysis.  
 
3.10. Genome-wide analysis shows miRNA targets with distinct structural and 
molecular properties 
 
Our findings indicated that shorter UTR length was correlated with greater site and 
flanking sequence openness in the Ago1 IP-enriched transcript set, whereas longer 
UTRs with higher site density were enriched among the transcripts upregulated 
following Ago1 depletion. This suggested there might be a fundamental difference in 
overall UTR composition in the Drosophila genome. 
 
With the help of Dr Molly Hammell, a similar analysis on miRNA target site density 
and openness on all annotated D. melanogaster UTRs were calculated for all miRNAs 
in Drosophila. Similar to the previous reports, a clear trend of increasing miRNA site 
density as a function of UTR length was observed (Stark et al., 2005). UTRs of 100-
300nt and 300-500nt had lower site densities than the median of all UTRs with sites 
(Fig 3.18A; bin 0.2: P=8e-133; bin 0.4: P=2.4e-6). For UTRs longer than 500nt, site 
density was higher than the median of all UTRs with sites (KS 2-sample, P<0.05, Fig 
3.18A). The increment of site density was gradually saturated for UTRs of more than 
1Kb in length. 
 
Next, the local structural properties flanking miRNA sites (upstream and downstream 
openness) were calculated and also showed substantial differences for targets with 
short and long UTRs. UTRs with sites were grouped by length and the enrichment for 
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openness was compared to all UTRs with sites. Similar to the analysis for IP-enriched 
set, correlation coefficients were calculated between enrichment and degree of 
structural openness over various window sizes (Fig 3.18B and Table 3.13). As shown 
in Fig 3.18B,  downstream sequences of UTRs ranging from 100nt to 700nt (“200-
600” bins) were more accessible and the accessibility enrichment started to dropped 
off from 700-900nt. Strikingly, the correlation eventually became negatively for longer 
UTRs in the 900-1100nt group, indicating a depletion for openness. The more detailed 
analysis of the openness for miRNA binding sites, upstream windows and downstream 
windows over various sizes were shown in Table 3.13. 
 
In summary, the above results suggested, firstly, site density increased with UTR 
length, to a maximum level of about 5/100 nt for all miRNAs; secondly, the 
accessibility of sites measured by sequence openness is higher in short UTRs and 
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Figure 3. 18 UTR length versus site density and structural openness in Drosophila 
mRNAs. 
(A) Sites/100 nt plotted versus UTR length. miRNA sites were predicted for all 
miRNAs. Annotated UTRs for 10705 genes in D. melanogaster were grouped into 200 
nt bins (0.2 represents UTRs of 100-300nt etc). Y-axis: median sites/100nt for UTRs 
in each bin (black squares). p<0.05 for all bins calculated using 2-tailed KS test.  
(B) Correlation of downstream openness as a function of UTR length. Surface plots 
showing correlation coefficients between the degree of downstream local nucleotide 
openness and enrichment in each binned UTR set compared to all UTRs with sites. Y-
axis: Pearson’s correlation coefficient. X-axis: 200 nt UTR bins ranging from 100-
1100 nt (91% of all UTRs are <1100nt). No correlations were observed for bins with 
longer than 1100nt, likely due to small sample populations.  
 




Table 3. 13 Genome-wide comparisons of upstream, downstream, and site 
openness (accessibility) of all predicted miRNA sites as a function of UTR 
length.  
All Drosophila melanogaster microRNAs were included for analysis and all annotated 
3' UTRs were folded using the Vienna RNAfold package. All UTRs were binned into 
200 nt bins (e.g "200" for 100-300nt, "400" for 300-500nt). The average percentages 
of local nucleotide openness were calculated for selected sequence windows (10-45) nt 
for upstream (B) and downstream (A) of each microRNA binding site and the binding 
site itself (C). Fold enrichments of openness were calculated for UTRs in each bin 
versus all annotated UTRs. Correlation coefficients were calculated to assess the 
correlation between degree of openness and enrichments for each UTR bin Vs all. This 
table lists the Pearson correlation coefficient and associated P-values. Data were 




In this part of my thesis, I have demonstrated an improved Ago1 IP protocol that is an 
effective method to identify microRNA targets. Intriguingly, targets enriched in Ago1 
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IP differ in structural and molecular properties from the target group identified by 
Ago1 depletion. The Ago1 IP-enriched set contains transcripts with shorter UTR, 
fewer sites, but with a greater degree of local structural openness around the binding 
site; on the contrary, transcripts upregulated after Ago1 depletion contain longer UTR 
with energetically weaker sites and poor structurally accessibility. Because these UTRs 
generally tend to have more sites located in close proximity, a synergistic regulation 
among these sites could be one reason for bypassing the need for strong binding 
energy and open local structure. A further genome-wide correlation between UTR 
length and structural accessibility was observed, suggesting perhaps an evolutionary 
selection for distinct miRNA regulatory mechanisms for genes with short UTRs versus 
genes with long UTRs.  Many miRNA targets are known to be regulated primarily at 
the mRNA level, others mainly at the protein level, yet it is not clear how the 
specificity is achieved. Our finding suggested the differences in target repression 
mechanisms might be dependent on the UTR composition and structural features of 
individual UTRs.  
 
One notable feature for long 3’UTRs is that they seems to be preferentially targeted for 
regulation by adenine/uridine-rich element binding proteins (AUBPs) in Drosophila 
(Cairrao et al., 2009). AUBPs destabilize mRNAs by recruiting RNA degradation 
enzymes. Interestingly, ~20% of Ago1 RNAi upregulated RNAs have conserved AU-
rich elements, a 2 fold over-representation (p=7e-12) vs  6.7% of the IP set (under-
representation p=0.02). It is tempting to speculate a fraction of Ago1 RNAi 
upregulated targets might be influenced by both AUBPs and miRNA machineries. 
Evidence on the interplay between AUBPs and miRNA regulation has been well 
documented. (Trabucchi et al., 2009; von Roretz and Gallouzi, 2008). 
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The findings suggested that UTR contextual features, like binding energy and 
structural accessibility varied from one target to another depending on UTR 
composition. Therefore, the computational programs, especially those utilizing these 
features for prediction, might be biased towards certain group of targets. For example, 
when the prediction algorithm mirWIP, which favors target site accessibility and 
hybrid energy, was applied to predict Drosophila miRNA targets, it did not seem to 
work well with respect to sensitivity and specificity using validated experimental 
target lists (Hammell M et al., personal communication). This is expected, as our study 
suggested a fraction of Drosophila miRNA targets are not structurally accessible and 
do not select for strong hybrid energy. Therefore, it is possible that more complex 
contextual features of miRNA-target interactions could have evolved in distinct 
species and one should be aware of differences in contextual features for evolutionary 
distant organisms when designing miRNA prediction algorithms. A systematic 
analysis of the interactions between contextual features, including synergistic 
regulation and structural openness for different species could improve the accuracy of 
prediction.  
 















Chapter 4 Functional characterization of bantam-Socs36E interaction leads to 





Cancer is a multi-step complex disease involving both genetic alterations and 
environmental contributions. One hallmark of cancer cells is the genomic instability, 
which caused many somatic mutations. The various mutational events represent one 
important driving force of cancer cells to acquire sustained proliferation and cellular 
division, evasion of tumor suppressive mechanisms, including programmed cell death 
and immune surveillance, angiogenic potential and metastatic capability (Hanahan and 
Weinberg, 2011). In order to achieve a better understanding of the mechanisms of 
cancer transformation, the detailed elucidation of mutational events affecting genes 
underlying the oncogenic or tumor suppressive signaling pathways, so called “driven 
mutation genes”, are of critical importance. On the other hand, many driver mutations, 
like RasV12, are found to be insufficient to cause neoplastic transformation in various 
human cancer transformation models. A concurrent activation of oncogenic RasV12 and 
suppression of genes involved in cellular defensive pathways, like P53 and P16, are 
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necessary to transform human cells (Schinzel and Hahn, 2008). This suggests cancer is 
a cooperating genetic event that involves multiple factors and molecular pathways.  
 
Drosophila has proven to be a useful model for discovery of genes relevant to cancer 
because many signaling pathways involved in tumor formation and metastasis are well 
conserved from flies to humans (reviewed in Liang et al., 2011; Paez et al., 2004). For 
example, activating mutations of the EGFR/Ras pathway occur in a wide variety of 
human cancers (Capdevila et al., 1994a; Deng, 2011; Martin-Belmonte et al., 2007; 
Rudrapatna et al., 2012). Interestingly, similar to human cancers, the Drosophila 
oncogenic form of Ras (RasV12) was found to be insufficient to direct tumor formation 
and metastasis without additional genetic changes (Brender et al., 2004; Miles et al., 
2011). Therefore, the Drosophila tumor model represents a relevant genetic platform 
to functionally dissect oncogenic cooperating events.  
 
In recent years, microRNAs have come to attention as potential oncogenes and as 
cooperating factors that can work together with other oncogenic stimuli. The miR-17-
92 microRNA cluster is overexpressed in lymphoma and has been shown to suppress 
Myc-induced apoptosis and promote tumor formation in lymphoma and pancreatic 
beta-cell tumor models (Mu et al., 2009). Similarly, miR-372-373 cluster have been 
shown to cooperate with oncogenic H-RasV12 to overcome p53 tumor suppressive 
function and promote cancer transformation (Voorhoeve et al., 2006).  
 
In this part of my thesis, I present the work that has been done in collaboration with Dr 
Hector Herranz, to show that the bantam microRNA and its target Socs36E act as 
cooperating factors in EGFR-driven tumorigenesis in a Drosophila tumor model. 
bantam is involved in control of cell proliferation and apoptosis during tissue growth 
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in Drosophila(Brennecke et al., 2003b; Hipfner et al., 2002). It is reported to be a key 
effector of the Hippo pathway (Nolo et al., 2006; Thompson and Cohen, 2006). 
bantam has recently also been identified as a target of the EGFR pathway. This placed 
bantam as a cross-talk node between EGFR and Hippo signaling in growth control 
(Herranz et al., 2012a). In this study, we identified Socs36E to be an important target 
of bantam in growth control. Socs36E functions as a negative feedback regulator 
limiting the EGFR signaling strength. Depletion of Socs36E under normal conditions 
has mild effects on growth. However, when EGFR is overexpressed, depleting 
Socs36E by RNAi produces uncontrolled tumorous overgrowth and neoplastic 
transformation. I further demonstrated that the human SOCS protein family member 
SOCS5 is a potential tumor suppressor in RasV12-driven cancer transformation in a 
human cellular transformation model. SOCS5 level is downregulated in a panel of 
breast cancer patients and its downregulation is associated with metastasis-free 
survival, uncovering an evolutionary conserved function of the SOCS protein family in 
tumorigenesis and its relevance to clinical cancer therapy.  
 
4.2 Depletion of bantam by microRNA sponge produces EGFR-like phenotypes 
 
miRNA sponges offer good opportunities to study miRNA loss-of-function in a 
temporally and spatially controlled manner (Loya et al., 2009). To facilitate the study 
of bantam function in the imaginal discs in vivo, I prepared a bantam sponge 
consisting of a dsRed transgene with 10 bantam binding sites in its 3’UTR. These sites 
contain a central bulge to prevent mRNA cleavage (Fig 4.1A; (Becam et al., 2011). To 
visualize sponge activity in vivo, I made use of a GFP sensor transgene with two 
perfect bantam target sites in its 3’UTR. bantam activity presumably can repress 
sensor GFP expression: high GFP levels indicated low bantam levels and vice versa 
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(Brennecke et al., 2003b). The UAS-bantamsponge transgene was expressed in the dorsal 
compartment of the wing disc using the dorsal compartment-specific driver, apterous-
Gal4 (apG4). The effectiveness of the UAS-bantamsponge was demonstrated by the 
elevation of GFP sensor levels in bantam depleted cells upon sponge expression (Fig 
4.1B). The sponge also reduced the size of the dorsal compartment, consistent with the 
role of bantam in tissue growth (Brennecke et al., 2003b; Hipfner et al., 2002).  
 
As expected, overexpression of bantam by MS1096-Gal4, which directs expression of 
the transgene throughout the wing, resulted in larger wings (compare Fig 4.2 B to A). 
Conversely, expression of the UAS-bantamsponge using MS1096-Gal4, resulted in 
smaller wings (Fig 4.2 D compared to Fig 4.2 A). There was also a change in the 
pattern of wing venation that was similar to the effects of reduced EGFR activity 
(Diaz-Benjumea and Garcia-Bellido, 1990; Guichard et al., 1999). As a confirmation, 
reduction of EGFR levels by expression of a UAS-EGFRRNAi transgene driven by 
MS1096-Gal4 produced phenotypes similar to the bantam sponge (Fig 4.2 C and D). 
Depletion of EGFR also led to a reduction in tissue size, confirming the role of EGFR 
signaling in tissue growth and cell survival (Prober and Edgar, 2000; Zecca and Struhl, 
2002). 
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Figure 4. 1 bantam microRNA sponge design and validation 
(A) Schematic representation of the bantam-sponge. 10 bantam binding sites (depicted 
as orange blocks) were cloned downstream of dsRed coding sequence in a pUAST 
vector. These sites have sequences complementary to bantam miRNA with a central 
mismatch. Mini-white was used as the genetic marker for transformation. 
(B) Confocal micrographs showing the wing pouch region of third instar wing 
imaginal discs that expressed the bantam sensor transgene. The sensor transgene is a 
GFP coding sequence with the addition of a stretch of nucleotide sequences containing 
two consecutive sites that are perfectly complementary to the bantam microRNA. The 
GFP is driven by a tubulin promoter and hence the transgene should be expressed 
ubiquitously. Due to the presence of bantam binding sites, changes in GFP levels at 
different regions within the wing disc should reflect the differences in bantam activity, 
with lower GFP level indicating higher bantam activity and vice versa. Left panel, 
apG4 drives GFP expression (UAS-GFP) specifically in the dorsal compartment of the 
wing disc. Gal4 protein shown in red.  Right panels, apG4 drives UAS-dsRED-
bantam-sponge specifically in the dorsal compartment. dsRED transgene expression 
was monitored to confirm tissue-specificity (marked in red). The GFP levels was 
strongly elevated in the dorsal compartment as compared to ventral, suggesting 
reduction in bantam  microRNA activity in the dorsal.  
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Figure 4. 2 bantam depletion by microRNA sponge resembled the effect of EGFR 
depletion in the wing 
Cuticle preparations of adult wings from flies of the indicated genotypes: (A) 
MS1096-Gal4/+; UAS-GFP/+; (B) MS1096-Gal4/+; UAS-bantam/+;  (C) MS1096-
Gal4/+; UAS-EGFRRNAi /+; (D) MS1096-Gal4/+; UAS-bantam-sponge/+. MS1096 
Gal4 drives transgene expression throughout the wing. Overexpression of bantam lead 
to milder overgrown and hence bigger wing as shown in (B). Depletion of bantam by 
sponge and EGFR by RNAi resulted in small wing, with some defect in wing venation 
in both cases (C and D). Scale bar, 1mm.  
 
4.3 Identification of Socs36E as a bantam target  
 
To identify the direct bantam targets that might be involved in growth control, I made 
use of the method that I developed for immunopurification of miRNA-containing 
ribonucleoprotein complexes (see Chapter 3). Antibodies to HA-tagged Ago1 were 
used to IP miRNPs from Drosophila S2 cells where bantam is abundant (Hong et al., 
2009). Socs36E mRNA was enriched by Ago1 IP (P<0.001) and has one potential 
bantam target site in its 3’UTR (Fig 4.3A). Socs36E had previously been identified 
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genetically as a negative regulator of the JAK-STAT and EGFR pathways (Almudi et 
al., 2009b; Michelson et al., 1998), implicating its potential role in growth regulation. 
 
To test whether bantam can directly regulate Socs36E, I constructed luciferase 
reporters with a 600 bp fragment of the 3’ UTR containing the predicted bantam target 
site (Fig 4.3B). Overexpression of bantam in S2 cells reduced the expression of the 
cotransfected Socs36E reporter by 44% (Fig 4.3B, p=0.005 compared to control). This 
downregulation was largely eliminated when the predicted bantam site was deleted as 
compare to the wild type reporter (Fig 4.3B, p=0.001). The mutant reporter was not 
significantly different than the empty vector control, suggesting the repressive effect of 
bantam on the wildtype reporter was dependent on the presence of the binding site. As 
expected, the positive control reporter, bantam sensor, which contains 2 perfect 
bantam sites, was effectively downregulated by 58% upon bantam overexpression 
(p=0.001). 
 
Next, to check whether bantam regulates endogenous Socs36E protein expression in 
vivo, the miRNA was misexpressed in dorsal-compartment of the wing using ap-Gal4 
and Socs36E protein expression was monitored by a polyclonal antibody against 
Socs36E. There was a uniform expression of Socs36E in the wing disc during the rapid 
proliferative phase in the early 3rd larval instar (Fig 4.4A, right panel in grey). 
Overexpression of bantam under apG4 control resulted in reduced Socs36E levels (Fig 
4.4B). Conversely, depletion of bantam by expression of a UAS-bantam-sponge led to 
an increase of Socs36E protein levels (Fig 4.4C). Therefore, bantam regulates Socs36E 
protein in vivo in the Drosophila wing. 
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Figure 4. 3 Socs36E is a direct bantam target 
(A) Diagram depicting the RA and RB isoforms of Socs36E mRNA. Orange denotes 
the 5’ non-coding exon; blue denotes coding exons. Red arrows denote the 3’UTRs of 
the two isoforms. Green indicates the position of the predicted bantam target site (not 
to scale). Predicted pairing between bantam and this site is shown below. Note that the 
site is atypical in having an extended region of 15 residues pairing to the 5’end of the 
miRNA without the typical central bulge, as well as in having a number of G:U base 
pairs (red).  A mutant version of the Socs36E 3’ UTR was generated with the pairing 
region deleted.  
(B) Histogram showing luciferase assays testing the functionality of the bantam site in 
the  Socs36E 3’UTR. S2 cells were transfected to express the luciferase reporter with 
or without bantam for wild type or mutant Socs36E 3’UTR ( approximately 600bp 
fragment). A bantam sensor with two perfect sites provided a positive control and the 
empty luciferase vector provided a negative control. The difference between wild type 
and mutant 3’UTRs was statistically significant (p = 0.001, Student’s T Test). Data 
represent mean ± SD from three independent experiments.  
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Figure 4. 4 bantam regulates Socs36E level in vivo 
(A-C) Confocal micrographs of the wing pouch region of early third instar wing discs 
labeled to visualize Socs36E protein by antibody staining (green on the left panels; 
shown separately in grey on the right panels). Gal4 protein is shown in red. Apterous-
gal4 (Ap-G4)) is a tissue-specific driver that directs Gal4 protein expression in the 
dorsal compartment of the Drosophila wing imaginal disc (as marked in A, left panel). 
(A) Control wing discs (genotype: Ap / +,  showing homogenous Socs36E throughout 
wing disc tissue; D, dorsal compartment, V, ventral compartment); (B) Dorsal-specific 
overexpression of bantam miRNA using Ap-G4, leading to dorsal-specific reduction 
of Socs36E protein level (right panel, in grey); (C) Dorsal-specific depletion of bantam 
activity by microRNA sponge using Ap-G4, which caused dorsal-specific upregulation 
of Socs36E protein expression (right panel, in grey).  
 
4.4 Socs36E is a negative growth regulator. 
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Socs36E was shown to be a direct target of bantam, thus it would be interesting to 
investigate how Socs36E affect growth. There is a reported null allele of Socs36EEY11 
available. The mutant was generated by imprecise excision of a P-element inserted at 
the Socs36E locus (Almudi et al., 2009a). Socs36EEY11 mutant flies had normal 
viability and showed a slight increase in wing size (Fig 4.5A and B, p < 0.001). The 
growth-inhibitory effect of Socs36E was further confirmed by Socs36E RNAi in vivo. 
Depletion of Socs36E by ap-Gal4 directed expression of a UAS-Socs36ERNAi 
transgene resulted in milderly increased growth (Fig. 4.6A and B, p = 0.002). 
Conversely, overexpression of Socs36E reduced growth (Fig. 4.6A and B; p < 0.001). 
Thus, Socs36E was a negative growth regulator in the Drosophila wing. 
 
If Socs36E’s role as a growth regulator was responsible for bantam’s growth-
promoting function, one would expect depletion of Socs36E to rescue the bantam loss-
of-function phenotype as presented in Fig 4.1b and 4.2D. As expected,  overexpression 
of the UAS-Socs36ERNAi transgene by ap-Gal4 could at least partially restore the 
smaller wing size caused by UAS-bantamsponge (Fig 4.6C;  p < 0.001). These results 
suggested that Socs36E is a functionally important target downstream of bantam 
involved in growth control. 
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Figure 4. 5 Socs36E mutant flies are slightly bigger in size  
(A) Cuticle preparations of adult wings from w- Canton S control flies and 
Socs36EEY11 homozygous mutants. Socs36EEY11  is a null allele generated by imprecise 
excision of a P-element inserted at the Socs36E locus (Almudi et al., 2009a).  
(B) The increase in wing size was ~10% and was statistically significant (p<0.001; n= 
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Figure 4. 6 Socs36E is a negative growth regulator that genetically interacts with 
bantam 
(A) Confocal microscopic images of the wing pouch region of third instar wing 
imaginal discs overexpressing GFP, Socs36ERNAi or Socs36E under apG4 control. 
Discs were labeled with anti-Gal4 (grey) to mark dorsal (“D”) cells. Arrows highlight 
the dimensions used to measure the relative sizes of D and V compartments.  
(B) Histogram plotting the average D/V ratio (mean ± SD). Reduction of D/V ratio in 
discs overexpressing Socs36E compared to the GFP control was statistically 
significant (p<0.001, Student’s t Test). Discs expressing Socs36ERNAi showed ~10% 
increase in D/V ratio and was statistically significant (p = 0.01).  
(C) Histogram plotting the average wing area from flies expressing GFP, the bantam-
sponge, 
or the bantam-sponge together with Socs36ERNAi under MS1096-Gal4 control. 
4.5 Socs36E is a negative feedback regulator of EGFR signaling  
 
One downstream effector of EGFR activity is the canonical MAPK pathway, leading 
to MEK-mediated phosphorylation of ERK. Antibodies to doubly phosphorylated 
ERK (dp-ERK) have been used to visualize MEK activity in vivo during growth and 
patterning of the imaginal discs (Gabay et al., 1997). As shown in Fig 4.7A, dp-ERK 
activity was detected in the majority of wing pouch cells with higher levels expressed 
along the presumptive 3rd and 4th wing veins and adjacent to the DV boundary (Fig 
4.7A). Reduction of Socs36E activity by ap-Gal4-driven UAS-Socs36ERNAi  led to a 
mild increase of dp-ERK levels in the dorsal compartment (Fig 4.7B, compare dorsal 
(D) to ventral (V)), indicative of elevated MAPK pathway activity. Similarly, 
depletion of Socs36E by dsRNA in S2 cells caused an increase in ERK 
phosphorylation (Fig.4.7C) and increased the level of sprouty mRNA (Fig.4.7D), a 
transcriptional target of the EGFR pathway (Casci et al., 1999). Therefore, Socs36E 
appears to negatively regulate EGFR/MAPK signaling activity which is consistent 
with previous demonstration of genetic interactions between EGFR and Socs36E 
(Callus and Mathey-Prevot, 2002).    
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Socs36E has also been shown to be a negative feedback regulator of JAK/STAT 
signaling (Callus and Mathey-Prevot, 2002; Karsten et al., 2002). Thus it might be 
interesting to check whether EGFR activity regulates Socs36E in a similar manner. 
Dorsal compartment-specific depletion of EGFR expression led to reduced Socs36E 
expression (Fig 4.8B, compare dorsal (D) to ventral (V) compartment). Conversely, 
overexpression of EGFR by ap-Gal4 caused increased expression of Socs36E in the 
dorsal compartment, and misfold of the tissue due to overgrowth (Fig 4.8C). Taken 
together, results from Fig 4.7 and Fig 4.8 suggested EGFR induces Socs36E 
expression while Socs36E acts to repress EGFR/MAPK activity, forming a negative 




                 
Figure 4. 7 Socs36E represses EGFR/MAPK signaling  
 (A, B) Confocal micrographs of the wing pouch region of third instar wing discs 
showing dp-ERK expression. (A) wild type control (B) apG4:UAS-Socs36ERNAi 
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Socs36E protein (red), dp-ERK (Green, shown separately in grey). D, dorsal 
compartment; V, ventral compartment, as separated by the white line in between.  
(C) Antibody to dp-ERK was used to probe immunoblots of cell lysates from S2 cells 
treated with dsRNA to GFP (control) or to Socs36E. dp-ERK levels were higher in 
Socs36E dsRNA-treated cells compared to control cells treated with GFP dsRNA. 
Anti-Kinesin was used to monitor loading.  
(D) Real-time quantitative PCR showing changes in mRNA levels of Socs36E and 
MAPK transcriptional target sprouty in S2 cells treated with dsRNA against Socs36E 
as compared to GFP control. Socs36E mRNA reduced to 50% and sprouty mRNA 
level upregulated up to 2.5 fold in Socs36E dsRNA-treated cells as compared to GFP 
control. Data represent mean ±  SD from three biological replicates. Asterisks indicate 




Figure 4. 8 EGFR also regulates Socs36E expression, thus forming a negative 
feedback loop. 
(A) Control wing discs (genotype: ap / +) showing homogenous Socs36E throughout 
wing disc tissue. Socs36E staining shown in red (left panel) and grey (right panel). 
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Gal4 protein stained in green (left panel). D, dorsal compartment; V, ventral 
compartment, as separated by the white line in between.  
(B) Dorsal-specific depletion of EGFR expression by ap-G4 driven RNAi construct 
against EGFR, leading to dorsal-specific reduction of Socs36E protein level (right 
panel, in grey);  
(C) Dorsal-specific overexpression of EGFR using Ap-G4, which caused dorsal-




4.6 Socs36E behaves as a tumor suppressor under conditions of elevated EGFR 
activity 
(Experiments presented in this section was conceptually formulated by Dr Stephen 
Cohen, Dr Hector Herranz and Hong Xin while the data was produced by Dr Hector 
Herranz) 
 
The evidence that Socs36E depletion in the wing caused mild increase in MAPK 
activity and Socs36E mutant animal is only slightly bigger in size suggests Socs36E on 
its own does not affect growth too much. EGFR overexpression alone caused tissue 
overgrown to 2-3 fold of the normal size without disrupting the epithelia morphology 
(Fig 4.9, middle panel). We hence speculated the increased Socs36E expression in 
EGFR overexpressing tissues might be blocking the excessive EGFR signaling activity 
and restricting EGFR-induced tissue overgrown. To test this, depletion of Socs36E by 
RNAi in EGFR-overexpressing discs was carried out to assess tissue growth. 
Expression of the UAS-Socs36ERNAi transgene together with EGFR overexpression 
caused massively tissue overgrowth (Fig 4.9, right panel), which is much bigger than 
expression of Socs36ERNAi alone (Fig 4.6A) or EGFR overexpression alone (Fig 4.9, 
middle panel). The synergistic effect of EGFR overexpression and Socs36E 
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rendered loss of epithelia structure (Fig 4.9, right panel), suggesting a possibility of 
neoplastic overgrowth. One hallmark of neoplasia is the general inhibition of cell 
death. To identify apoptotic cells, we used antibody to detect the activated form of 
Caspase-3 (cas-3-act). The discs expressing EGFR alone caused a strong induction of 
apoptosis (Fig 4.10A). Caspase-3 activation was greatly reduced in the discs 
coexpressing EGFR with Socs36ERNAi transgene (Fig 4.10B, compared to A). Thus, 
reduced Socs36E activity suppressed EGFR-induced apoptosis.  
 
Loss of epithelial integrity is associated with cancer transformation and metastasis 
(reviewed in (Thiery et al., 2009). To assess the changes in apico-basal cell polarity of 
the wing disc tissues, E-cadherin and Dlg localization was visualized by 
immunostaining. The EGFR-overexpressing tissues had normal apical localization of 
E-cadherin and Dlg as compared to wildtype (compare Fig 4.10, E, compared to wild 
type in D). In contrast, apico-basal polarity were disrupted in the discs coexpressing 
EGFR with the Socs36ERNAi transgene as shown by the loss of E-cadherin and Dlg 
expression in these tissue (Fig 4.10F). The loss of these polarity gene expression was 
not seen in expression of the Socs36ERNAi transgene alone (data not shown). 
Furthermore, these changes were accompanied by elevated expression of snail, a 
molecular marker of epithelial-mesenchymal transition (reviewed in (Barrallo-Gimeno 
and Nieto, 2005; Peinado et al., 2007), and a robust upregulation of matrix 
metalloprotease 1 mRNA in the tissue coexpressing EGFR with the Socs36ERNAi 
transgene  (Fig4.10C).  
 
Taken together, the inhibition of apoptosis, loss of epithelia integrity and elevation of 
EMT and metastatic signature genes strongly suggested that EGFR cooperates with 
Socs36E to induce neoplastic transformation of the wing disc cells. 






Figure 4. 9 Depletion of Socs36E in EGFR overexpressing wing discs caused 
dramatic tissue overgrown  
Low magnification confocal micrographs showing third instar wing imaginal discs 
labeled with DAPI. Genotypes as indicated: WT = normal control; apG4 UAS-EGFR, 
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Figure 4. 10 Depletion of Soce36E in EGFR overexpressing wing lead to 
neoplastic transformation 
(A, B) Confocal micrographs of third instar apG4 UAS-EGFR, UAS-GFP and apG4 
UAS-EGFR, UAS-Socs36ERNAwing discs. Antibody to activated Caspase 3 (Cas-3) 
shown in green and separately in grey (at right).  
(C) Quantification of mRNA levels of mmp1 and snail as measured by real time 
quantitative PCR. RNA was prepared from discs of the indicated genotypes. Data was 
normalized to rp49.  
(D-F) Optical cross sections of third instar wing discs labeled with DAPI to show the 
nuclei (blue and grey), anti-DE-cadherin (red and grey), and Dlg-GFP (green and 
grey). Genotypes: (D) wild type control (E) apG4 UAS-EGFR, UAS-GFP (F) apG4 
UAS-EGFR, UAS-Socs36ERNAi.  (Data  provided by Dr Hector Herranz) 
 
4.7 Human SOCS5 behaves as a candidate tumor suppressor in an EGFR/RAS-
dependent cellular transformation assay  
 
The identification of Socs36E as a cofactor that promoted transformation from benign 
hyperplasia to neoplastic growth in the fly model prompted me to ask whether its 
human orthologs might have a similar role. The mammalian SOCS protein family has 
a total of 8 members, including SOCS1-7, and CISH. SOCS4 and SOCS5 are the 
closest homologs of Drosophila Socs36E. To test the effects of depleting SOCS 
proteins,  I made use of an in vitro assay for transformation of primary human BJ 
fibroblast cells based on anchorage independent colony growth in soft agar (Hahn et 
al., 1999; Hahn et al., 2002; Voorhoeve and Agami, 2003). The cells were transduced 
with retroviral constructs to direct expression of (1) hTERT, which encodes the 
catalytic subunit of the telomerase to allow replicative immortality; (2) Inducible 
oncogenic H-RasV12 fused to the ligand binding domain of the Estrogen Receptor (H-
RasV12-ER), to activate RasV12 signaling upon addition of 4 hydroxy-tamoxifen (TAM, 
(Caussinus and Gonzalez, 2005); (3) shRNAs to deplete p53 and p16, to overcome 
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RasV12-induced growth arrest and confer colonigenic outgrowth; (4) SV40 small T 
antigen, which allows anchorage-independent growth in soft agar. As expected, 
activation of RasV12-ER by addition of 4 hydroxy-tamoxifen (10-7 M) promoted 
colony formation in soft agar (Fig 4.11A and B, Vector controls).  
 
It happens SOCS5 is much more abundantly expressed and SOCS4 expression is 
relatively low in BJ cells (unpublished microarray data from Dr Mathijs Voorhoeve 
lab), thus I chose SOCS5 as an example to investigate. I made shRNA vectors 
targeting two independent sites in human SOCS5. Both shRNAs were effective in 
depleting SOCS5 mRNA to 50%-60% of control levels upon transduction into BJ cells 
(measured by quantitative real time PCR, p<0.05 for each shRNA, Fig 4.11D). 
Depletion of SOCS5 potentiated the effects of RasV12 activation, and led to ~2 fold 
increase in the number of colonies compared to vector control (Fig 4.11A; P = 0.002 
for shRNA-1, P = 0.006 for shRNA-2).  
 
I also tested the ability of SOCS5 depletion to promote colony formation in cells 
stimulated with EGF ligand to activate the EGFR/MAPK pathway in place of RasV12 
induction. Use of EGF ligand produced fewer and smaller colonies in the 
transformation assay when the same number of cells used per cell (Fig 4.11B, 10,000 
cells/well), but again the effects of ligand activation were potentiated by shRNA-
mediated depletion of SOCS5 (Fig 6A; P = 0.009 for shRNA-1 and 0.02 for shRNA-
2). Depletion of SOCS5 alone was not sufficient to promote colony formation, 
suggesting that it acts cooperatively with EGFR/RasV12 pathway activation in cell 
transformation. This was surprisingly consistent with the function of the Drosophila 
homolog of SOCS5, Socs36E, as a conserved oncogenic cooperating factor of the 
EGFR pathway.  




Figure 4. 11 Depletion of SOCS5 enhanced soft agar colony formation in primary 
human fibroblast cells 
(A, B) Representative images showing colonies of BJ/ET-RASV12-ER-hTERT cells 
grown in soft agar with the indicated shRNA treatments: empty vector control, two 
independent shRNAs targeting SOCS5 (shRNA-1 and shRNA-2). (A) Cells were 
treated with 10-7 M hydroxy-tamoxifen to activate RasV12 (+TAM, upper panels) or left 
untreated (-TAM, lower panel). (B) Cells were treated with 0.1 microgram/ml EGF 
(+EGF, upper panel) or left untreated (-EGF, lower panel). Photographs were taken 
using the same microscope settings and analyzed comparably. 
(C) Colony formation in soft agar produced by the indicated treatments as shown in A 
and B. Data were normalized to the empty shRNA vector control and presented as % 
of control colony number. Data represent mean ± SD from three independent retroviral 
transduction experiments. Student’s T Test was used to assess differences between 
SOCS5 shRNA treatments and empty-vector control. For colony quantification in 
TAM treated group, P = 0.002 for SOCS5 shRNA-1; P = 0.006 for SOCS5 shRNA-2; 
For colony quantification in EGF treated group, P = 0.009 for SOCS5 shRNA-1; P = 
0.02 for SOCS5 shRNA-2. 
(D) Quantitative real-time PCR to measure the efficacy of shRNA-mediated depletion 
of SOCS5 (Student’s T Test, P = 0.004). mRNA fold change was shown relative to 
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empty-vector control for three independent biological replicates. Data were normalized 
to GAPDH and the relative level of TBP was used as a negative control.    
 
4.8 SOCS5 expression is downregulated in breast cancer and associated with 
metastatic-free survival  
 
The finding that depletion of SOCS5 can potentiate the effects of RasV12 or EGFR in 
the cellular transformation assay raised the possibility that alterations in SOCS5 levels 
might be a cooperating factor in EGFR-dependent human carcinogenesis. ErbB family 
genes, including EGFR, are frequently amplified, overexpressed or mutationally 
activated in breast cancer (Hynes and MacDonald, 2009). I first investigated whether 
SOCS5 is mutated in certain cancer types. As summarized in Fig 4.12A, SOCS5 
somatic mutation is only found in a few cancer types at relatively low frequency: Lung 
carcinoma (1/145), Ovary carcinoma (2/60), and Glioma (1/45) (data downloaded from 
Catalog of Somatic Mutations in Cancer: 
http://www.sanger.ac.uk/genetics/CGP/cosmic/). With help from Zhang Rui, I then 
further examined mRNA expression levels of SOCS5 in various cancer types. Large 
cohorts of data pooled from two different microarray platforms (the human U133plus2 
and U133A platforms) showed that SOCS5 was consistently downregulated in breast 
cancer patient samples as compared to normal (Fig4.12B; data collected from GENT 
database: http://medical-genome.kribb.re.kr/GENT/search/search.php). The U133 
plus2 platform contained up to 2658 cancer samples and 271 normal tissues (P= 1.2E-
29) while the U133A platform covered 2635 cancer samples and 91 normal controls (P 
= 3.1E-03). This suggests that SOCS5 was on average downregulated in the clinical 
breast cancer samples. 
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ErbB2/HER2 status is an important clinical parameter used to classify breast cancer 
patients for therapy (Esteva et al., 2010).  Because SOCS5 has been shown to affect 
receptor turnover (Kario et al., 2005; Nicholson et al., 2005), we looked for a 
correlation between SOCS5 levels and ErbB2 status in breast cancer in a collection of 
13 clinical datasets compromising 962 patient samples (Fig4.12C, Table 4.1). SOCS5 
expression was significantly lower in the ErbB2 positive patient group as compared to 
the ErbB2 negative group (Fig4.12C; Paired Student’s T test, P = 0.003). Similarly, 
SOCS5 levels were also lower in the control group compared to the triple negative 
ErbB2/Estrogen Receptor/Progesterone Receptor group (Fig4.12D; P = 0.026). These 
findings suggested an association between downregulation of SOCS5 and 
ErbB2/Estrogen Receptor/Progesterone Receptor positivity, which might provide 
important clues for breast cancer patient stratification and drug treatment. No such 
relationship was found for other closely related SOCS family members.  
 
Furthermore, a comprehensive analysis of two independent primary tumor array 
datasets from a total of 990 patients suggested that patients with higher SOCS5 
expression exhibited a better metastasis-free survival profile than patients with lower 
SOCS5 levels (Fig 4.13, A-D). Hence, SOCS5 expression levels might contribute to 
breast cancer pathogenesis and could have clinical relevance.  
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Figure 4. 12 SOCS5 mutation rates and mRNA expression in cancer  
(A) SOCS5 somatic mutation profile was downloaded from Catalog of Somatic 
Mutations in Cancer: http://www.sanger.ac.uk/genetics/CGP/cosmic/ and summarized 
in table format. Mutation tissue types were listed and mutation rate was presented as % 
of total : X/Y. X denoted number of samples with SOCS5 mutations and Y denoted 
total samples sequenced.  
(B) Large cohorts of data pooled from two different microarray platforms (the human 
U133plus2 and U133A platforms was extracted from GENT database (http://medical-
genome.kribb.re.kr/GENT/search/search.php) and plotted as Box and whisker plots, 
show the 1st quartile and 3rd quartile (boxes) and the range of non-outliers (whiskers). 
The U133 plus2 platform contained up to 2658 cancer samples and 271 normal tissues 
(Cancer Vs Normal, estimated P= 1.2E-29) while the U133A platform covered 2635 
cancer samples and 91 normal controls (Cancer Vs Normal, estimated P = 3.1E-03).  
(C, D) Median-centered expression (log2 scale) of SOCS5 mRNA from 14 published 
array datasets of primary tumor samples were extracted from the Oncomine database, 
categorized as ErbB positive (Y-axis, C) versus ErbB negative (X-axis, C) or Other 
biomarker Status (Y-axis, D) versus ErbB/ER/PR negative (X-axis, D) and presented 
as pairwise diagonal plots. Paired Student’s T tests were performed, P = 0.0026 (C); P 
= 0.026 (D). 






Figure 4. 13 SOCS5 expression is associated with metastatic-free survival in 
breast cancer patients 
(A-D) Kaplan–Meier analysis of metastasis-free survival using the SOCS5 median 
expression status in two independent datasets. “SOCS5 high” indicated expression 
value higher than the median (A, C) or third quartile (B, D) while “SOCS5 Low” 
means lower than median expression level (A, C) or first quartile (B, D). Outcomes 
were censored at 12 years. Dataset-1 (A, B) refers to NKI dataset which contains 295 
breast cancer samples(van de Vijver et al., 2002). Dataset-2 (C, D) refs to a collection 
of 695 clinical breast cancer samples extracted from four independent studies (Ivshina 
et al., 2006; Loi et al., 2008; Pawitan et al., 2005; Schmidt et al., 2008). Data were 
analyzed as described previously (Li et al., 2010; van Vliet et al., 2008). The log-rank 
test was used to determine statistical significance.   




Table 4. 1  Listing of Log2 median-centered SOCS5 expression levels for each 
indicated dataset.  
 Data extracted from oncomine (https://www.oncomine.org/resource/login.html). 
Paired Student’s T test was performed to identify the statistical significance of 
differences between: (1)ErBB+ Vs ErBB negative group; (2) Other biomarker Status 
Vs ErBB/ER/PR negative group. N.A, not available. The last column showed 
references and number of samples used in each dataset. Pairwise diagonal plots were 




Cancer cells possess unlimited proliferative potential and evasion of intrinsic cellular 
defense mechanisms. This is achieved by alternations of molecular machineries at 
multiple levels. One such mechanism utilized by cancer cells is the accumulation of 
genomic mutations during clonal evolution (Hanahan and Weinberg, 2000). The 
cancer genome sequencing efforts have been greatly accelerated by the next-generation 
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sequencing technologies. The results of these studies provide ample opportunities for 
the discovery of cancer-associated genetic alterations. However, it is found that cancer 
cells possess many mutations concurrently. The “driver mutation” genes (known as 
oncogenes or tumor suppressors), which play a dominant role in cancer transformation 
and progression, are often accompanied by thousands of “passenger mutations”, some 
of which do not have any effect while others might acts as cooperating factors of the 
“driver mutation” genes. Those cooperating factors directly participate in 
tumorigenesis by effectively modulating the strength of oncogenic stimuli and 
inhibition of multiple tumor suppressive functions. Tremendous efforts have been 
devoted to identifying such oncogenic cooperating factors involved in carcinogenesis, 
which could shed light on the understanding of cancer biology and development of 
therapeutical strategies against various cancer types (Stratton, 2011) .   
   
SOCS5 might be one such oncogenic cooperating factor. Lower SOCS5 levels 
correlated with cancerous tissues as compared to normal. If this correlation reflects 
accumulation of ErbB proteins, then,“SOCS5 low” cancer cells might be more 
sensitive to drugs targeting the ErbB receptor. Further investigations will be needed to 
test whether SOCS5 levels modulate drug response in vitro and in vivo, and whether 
SOCS5 status might provide as a predictive biomarker for stratifying patients treated 
with these drugs in the clinic. The availability of multiple biomarkers and clinical 
parameters could provide important guidance information on the usage of anti-ErBB 
drugs on ErBB-amplified cancer patients such as breast cancer. An appropriate choice 
of drugs and therapeutically strategies based on individual genetic and genomic status 
would be central to the eventual development of personalized medicine (Capdevila et 
al., 1994b; Karn et al., 2011). 
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Heterodimerization of different ErbB proteins confers specificity of signal activation 
in different types of cancers. For example, ErbB2 overexpression is more typical of 
breast cancer. Heterodimerization between ErbB2 and ErbB3 is the predominant 
combination in breast cancer cells, while in non-small cell lung cancer the ErbB1 and 
ErbB3 combination is more common (Gassama-Diagne et al., 2006). The correlation 
between reduced SOCS5 levels and ErbB-positive breast cancer suggests that 
alterations leading to lower SOCS5 levels may contribute to disease progression. 
Interestingly, we found no evidence for downregulation of SOCS5 in other cancer 
types which contain frequent ErbB amplification or activating mutations, including 
lung cancer and ovarian cancer, perhaps suggesting a functional specificity of SOCS5 
for ErbB2 complex activation in breast cancer pathogenesis. To date, mutations 
inactivating SOCS5 have been found only infrequently in a few cancer types, 
suggesting perhaps the SOCS5 mRNA downregulation due to epigenetic alterations or 
miRNA-mediated post-transcriptional regulations, is the predominant mechanism in 
breast cancer cells  (Fig 4.12A).  
 
Identification of the tumor suppressive activity of Socs36E followed from its 
identification as a target of a growth regulatory miRNA. Although bantam miRNA is 
not obviously conserved in mammals, it acts through a conserved target. The 
functional similarity between Drosophila Socs36E and human SOCS5 in tumor 
suppression suggests miRNA target identification could be a power tool in uncovering 
novel components in cancer, regardless of evolutionary conservation of the miRNA 
sequences. The mode of oncogenic cooperation between miRNAs and driver 
oncogenes has been documented. For examples, c-Myc cooperates with mir-17/92 
cluster in a mouse model of B-cell lymphomas and  mir-372~373 cooperates with H-
RasV12 in an in vitro cancer transformation of human fibroblast cells (Mu et al., 2009; 
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Voorhoeve et al., 2006). Interestingly, the mammalian SOCS5 contains predicted 
binding sites for several miRNAs including mir-19 and mir-9 (TargetScanHuman 5.2). 
Both mir-19 and mir-9 are shown be upregulated in breast cancer cells. mir-19 was 
shown to repress PTEN mRNA and affect drug sensitivity while mir-9 was shown to 
repress DE-cadherin and confer metastasis and tumor invasion (Ma et al., 2010; Rody 
et al., 2011). It is conceivable that both miRNAs might target SOCS5, and thereby 
contribute to tumor formation in breast cancer. Therefore, miRNAs from both fly and 
human might convergently target highly conserved growth control machineries to 
maintain pathway homeostasis. Aberrant expression of miRNAs could lead to 




















Chapter 5 Conclusion and Future work 
 
In the first part of my thesis, I have employed a biochemical approach to identify 
targets based on the physiological association of miRNAs and targets in the 
Ago1/GW182 effector complex. IP-ed RNA from the Ago1 complex was subjected to 
microarray profiling from which I identified hundreds of mRNAs specifically enriched 
in the Ago1-IP as compared to mock IP. The IP-ed mRNAs preferentially contained 
binding sites for S2 cell-expressing miRNAs and was enriched for validated positive 
targets. I further validated IP-enriched targets for one particular miRNA: mir-184, 
which is highly expressed in S2 cells using Q-PCR and the luciferase assay. 
Surprisingly, when we compared our pool of Ago1 IP data with the microarray data 
from Ago1-depleted S2 cells carried out by another group, we found limited overlap 
between Ago1 IP –enriched genes and Ago1-depletion upregulated genes. They differ 
substantially in their 3’UTR length, enriched seed types, and local structural openness 
flanking the miRNA binding sites. It is interesting that the two groups of miRNA 
targets, both of which could be physiologically important, each possess distinct 
structural and molecular signatures.  
 
Genome-wide computational analysis of all predicted Drosophila miRNA targets 
suggested a clear correlation between UTR length and miRNA site accessibility, 
providing an important clue for further optimization of miRNA prediction algorithms. 
It would be rather interesting to investigate whether such a correlation also holds true 
for miRNA-target pairs in other species. Improved versions of the Ago IP method, like 
the ones using cross-linking approaches coupled to next generation sequencing, would 
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allow a higher resolution of genome-wide target site identification and mapping. Our 
S2 cell Ago1 IP-enriched target list could provide useful information for further 
functional validation of individual miRNA-target pairs using Drosophila genetics and 
biochemical tools.  
 
In the second part of my thesis, I made use of the Ago1 IP-enriched target list to 
identify Socs36E as a functionally important bantam target involved in growth control. 
I showed that bantam directly targets Socs36E by regulating its 3’UTR region and 
regulates Soc36E protein level in vivo. Co-depletion of bantam and Socs36E partially 
rescued the reduction in wing size in bantam loss-of-function mutants, suggesting 
bantam-Socs36E interaction is important for tissue growth control. We further 
demonstrated that Socs36E and EGFR form a negative feedback loop and Socs36E 
acts as a “brake” to repress excessive EGFR signaling. The importance of this 
feedback control was demonstrated in the wing: once the “brake” is removed by 
Socs36E depletion, EGFR overexpression leads to uncontrolled tumorous overgrowth 
and neoplastic transformation. We further uncovered the SOCS protein family as 
evolutionarily conserved oncogenic cooperating factors of EGFR/RasV12- mediated 
cancer transformation in both Drosophila and human.  One of the human orthologs of 
Socs36E, SOCS5, is a potential cooperating tumor suppressor of RasV12 -driven human 
cancer transformation. The clinical relevance of SOCS5 in human cancer is 
demonstrated that SOCS5 is downregulated in breast cancer samples and associated 
with ErBB/ER/PR status. Lower SOCS5 expression correlates with poor metastatic-
free survival in breast cancer patients.  
 
It might be interesting in the future to investigate whether other family members of 
SOCS proteins act in a similar manner to SOCS5 or they are functionally distinct. If 
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there are well-annotated clinical samples available, it could be quite interesting to 
analyse whether SOCS5 level correlates with anti-ErBB drug resistance and/or tumor 
grade, metastatic index and other patient parameters. This might serve as important 
information for stratification of cancer patient treatment. The fact that Socs36E is a 
negative feedback regulator of Jak/STAT and EGFR/Ras pathways suggested SOCS 
proteins might act as network nodes for multiple signaling cross talks and inputs. It is 
tempting to investigate which signaling pathways are simultaneously controlled by the 
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